

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/001883

International filing date: 21 January 2005 (21.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/538,322
Filing date: 21 January 2004 (21.01.2004)

Date of receipt at the International Bureau: 03 March 2005 (03.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1287959

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

February 22, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/538,322

FILING DATE: *January 21, 2004*

RELATED PCT APPLICATION NUMBER: *PCT/US05/01883*



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. **ER 388208213 US**

22087 U.S. PTO
60/538322

012104

INVENTOR(S)					
Given Name (first and middle (if any))		Family Name or Surname		Residence (City and either State or Foreign Country)	
KRISTEN		PIERCE		BURLINGAME, CA	
Additional inventors are being named on the _____ / _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number: <div style="border: 1px solid black; width: 200px; height: 30px; display: inline-block;"></div>					
OR					
<input checked="" type="checkbox"/> Firm or Individual Name		FIVE PRIME THERAPEUTICS / ATTN: DR. AMY L. BOI COLLINS			
Address					
Address		951 GATEWAY BLVD			
City		SOUTH SAN FRANCISCO		State	CA
Country		USA		Zip	94080
		Telephone	(650) 592-5923	Fax	650-624-5901
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages		81		<input type="checkbox"/> CD(s), Number _____	
<input type="checkbox"/> Drawing(s) Number of Sheets		_____		<input checked="" type="checkbox"/> Other (specify) ABSTRACT	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE Amount (\$)	
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees.				<div style="border: 1px solid black; padding: 5px; text-align: center;"> \$580.00 </div>	
<input type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: _____					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

[Page 1 of 2]

Respectfully submitted,

SIGNATURE

Amy L. Boi Collins

TYPED or PRINTED NAME

AMY L. BOI COLLINS

TELEPHONE

650-624-5923

Date

21 JAN 2004

REGISTRATION NO.

37,370

(if appropriate)

Docket Number:

FP20040002

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PROVISIONAL APPLICATION COVER SHEET
Additional Page

PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number

FP20040002

INVENTOR(S)/APPLICANT(S)

Given Name (first and middle (if any))	Family or Surname	Residence (City and either State or Foreign Country)
LEWIS T. AMY L. HONGBING PIERRE	WILLIAMS TSUI COLLINS ZHANG BEAURANG	MILL VALLEY, CA OAKLAND, CA ALBANY, CA GREENBRAE, CA

[Page 2 of 2]

Number 2 of 2

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

UNITED STATES PROVISIONAL PATENT APPLICATION

for

PHARMACEUTICAL COMPOSITIONS CONTAINING ANTAGONISTS TO LRP4, LRP8 OR
MEGALIN FOR TREATMENT OF DISEASES

by

KRISTIN PIERCE,
LEWIS T. WILLIAMS,
AMY L. TSUI COLLINS,
PIERRE BEAURANG,
and
HONGBING ZHANG

**PHARMACEUTICAL COMPOSITIONS CONTAINING ANTAGONISTS TO LRP4, LRP8
OR MEGALIN FOR TREATMENT OF DISEASES**

FIELD OF THE INVENTION

BACKGROUND OF THE INVENTION

[0001] The present invention relates to pharmaceutical compositions for the treatment of a disease. Compositions of the invention may contain a pharmaceutically acceptable carrier and at least one modulator that will bind to or interfere with the activity of megalin, hereinafter referred to as “LRP2,” LRP4, LRP8 and active fragments thereof. The invention further provides modulators, such as antibodies, RNAi molecules, anti-sense molecules and ribozymes. Additionally, the invention includes methods of treatment of diseases, such as proliferative and degenerative diseases, and methods of administration of the compositions of the invention.

BACKGROUND OF THE INVENTION

[0002] The LDL receptor-related protein (LRP) is larger than but structurally similar to other members of the LDL receptor gene family, a family of endocytic receptors (Willnow et al., *Nat. Cell Biol.*, 1:E157-E162 (1999); Herz et al., *Nat. Rev. Neurosci.*, 1:51-58 (2000)). Whereas the LDL receptor, the founding member of this family, appears to act solely in lipoprotein metabolism, the LRP and some known members of this family appear to have other distinct functions.

[0003] Known LRP members, like many members of the LDL receptor gene family, contain five common structural units shown that typically include, for example, a ligand-binding (complement) type cysteine-rich repeats, an epidermal growth factor (EGF) receptor-like cysteine-rich repeats, YWTD domains, a single membrane-spanning segment, and a cytoplasmic tail that harbors between one and three NPxY motifs. Ligand-binding-type repeats in LRP occur in clusters containing between two and eleven individual repeats. Many of the known ligands for LRP, see, for example, Herz et al., *J. Clin. Invest.*, 108:779-784 (2001), (Table 1), for which the binding sites have been mapped, interact with these

ligand-binding-type domains (Neels et al., *J. Biol. Chem.*, 274:31305-31331 (1999)). These are followed by EGF precursor homology domains, which consist of the two EGF repeats, six YWTD repeats that are arranged in a propeller-like structure (Springer, T.A., *J. Mol. Biol.*, 283:837-862 (1998)), and another EGF repeat. Six EGF repeats precede the single membrane-spanning segment. The cytoplasmic tail contains two NPxY motifs that serve as docking sites for the endocytosis machinery and for cytoplasmic adaptor and scaffolding proteins involved in signaling events (Trommsdorff et al., *J. Biol. Chem.*, 273:33556-33560 (1998)).

[0004] At present, the role LRP plays in disease is not fully appreciated. It is therefore desirable to clarify this role and design methods and compositions that are useful to address LRP associated disease.

SUMMARY OF THE INVENTION

[0005] It is one of the objects of the present invention to provide pharmaceutical compositions for treatment of a disease, such as a proliferative disease or degenerative disease. The invention employs modulators, such as antibodies for treatment of such diseases.

[0006] The antibodies of the invention can be produced *in vitro* or *in vivo*. For example, the present invention features an antibody produced in a cell-free expression system, a prokaryote expression system or a eukaryotic expression system described herein.

In accordance with one of the objectives of the present invention, there is provided:

[0007] 1. A pharmaceutical composition for treatment of a disease, wherein the composition comprises a pharmaceutically acceptable carrier and at least one modulator that binds to or interferes with the activity of LRP4, LRP8, LRP2 (megalin) and active fragments thereof.

[0008] 2. The composition of 1, wherein the modulator is selected from the group consisting of: a small molecule, an RNAi molecule, an anti-sense molecule, and a ribozyme.

[0009] 3. The composition of 1, wherein the modulator is an antibody.

[0010] 4. The composition of 3, wherein the antibody is a human or humanized antibody.

- [0011] 5. The composition of 3, wherein the antibody is a polyclonal antibody.
- [0012] 6. The composition of 3, wherein the antibody is a monoclonal antibody.
- [0013] 7. The composition of 3, wherein the antibody is a single chain antibody.
- [0014] 8. The composition of 3, wherein the antibody is a fragment of an immunoglobulin and the fragment binds specifically to an antigen or an epitope.
- [0015] 9. The composition of 3, wherein the antibody comprises at least one domain selected from the group consisting of a variable region of an immunoglobulin, a constant region of an immunoglobulin, a heavy chain of an immunoglobulin, a light chain of an immunoglobulin and an antigen-binding region of an immunoglobulin.
- [0016] 10. The composition of 1, wherein the disease is a proliferative disease.
- [0017] 11. The composition of 10, wherein the proliferative disease is tumor or psoriasis.
- [0018] 12. The composition of 11, wherein the proliferative disease is a tumor.
- [0019] 13. The composition of 12, wherein the tumor is selected from the group consisting of splenic tumor, cervical tumor, leukemia, stomach tumor, liver tumor, thyroid tumor, skin tumor, breast tumor, lung tumor, kidney tumor, brain tumor, colon tumor, ovarian tumor, pancreatic tumor, and lymphoma.
- [0020] 14. The composition of 12, wherein the tumor is an colon tumor.
- [0021] 15. The composition of 12, wherein the tumor is a liver tumor.
- [0022] 16. The composition of 12, wherein the tumor is a lung tumor.
- [0023] 17. The composition of 12, wherein the tumor is an ovarian tumor.
- [0024] 18. The composition of 12, wherein the tumor is kidney tumor.
- [0025] 19. The composition of 12, wherein the tumor is a pancreatic tumor.
- [0026] 20. The composition of 1, wherein the disease is a degenerative disease.
- [0027] 21. The composition of 20, wherein the degenerative disease is a degenerative neural disease.
- [0028] 22. The composition of 21, wherein the degenerative neural disease is Alzheimer's disease.
- [0029] 23. The composition of 1, wherein the modulator is a nucleic acid molecule.
- [0030] 24. The composition of 3, wherein the antibody specifically binds to or interferes with the activity of a sequence selected from the group consisting of: SEQ ID NOs:10-18 and SEQ ID NOs:28-126.

- [0031] 25. The composition of 3, wherein the antibody specifically binds to or interferes with the activity of a ligand of at least one selected from the group consisting of: LRP4, LRP8, LRP2 (megalin) and active fragments thereof.
- [0032] 26. A method of treatment of a disease in a subject, comprising the steps of:
- (a) providing the composition of any of 1 – 9 and 23 – 25; and
 - (b) administering the composition to the subject.
- [0033] 27. The method of 1, wherein the disease is a proliferative disease.
- [0034] 28. The method of 27, wherein the proliferative disease is tumor or psoriasis.
- [0035] 29. The method of 28, wherein the proliferative disease is a tumor.
- [0036] 30. The method of 29, wherein the tumor is a colon tumor.
- [0037] 31. The method of 30, wherein the composition comprises an antibody that specifically binds to or interferes with the activity of at least one selected from the group consisting of: LRP4, LRP8, and active fragments thereof.
- [0038] 32. The method of 31, wherein the antibody specifically binds to or interferes with at least one selected from the group consisting of SEQ ID NOs:10-15, 17-18, 28-48, and 112-126.
- [0039] 33. The method of 29, wherein the tumor is a liver tumor.
- [0040] 34. The method of 33, wherein the composition comprises an antibody that specifically binds to or interferes with the activity of at least one selected from the group consisting of: LRP4, LRP8, and active fragments thereof.
- [0041] 35. The method of 34, wherein the antibody specifically binds to or interferes with at least one selected from the group consisting of SEQ ID NOs:10-15, 17-18, 28-48, and 112-126.
- [0042] 36. The method of 29, wherein the tumor is selected from the group consisting of: lung tumor, splenic tumor, cervical tumor, stomach tumor, breast tumor, leukemia and lymphoma.
- [0043] 37. The method of 36, wherein the composition comprises an antibody that specifically binds to or interferes with the activity of at least one selected from the group consisting of: LRP8 and active fragments thereof.
- [0044] 38. The method of 37, wherein the antibody specifically binds to or interferes with at least one selected from the group consisting of SEQ ID NOs:10-15 and SEQ ID NOs:112-126.

- [0045]
- [0046] 39. The method of 29, wherein the tumor is an ovarian tumor.
- [0047] 40. The method of 39, wherein the composition comprises an antibody that specifically binds to or interferes with the activity of at least one selected from the group consisting of: LRP2 (megalin), LRP8, and active fragments thereof.
- [0048] 41. The method of 40, wherein the antibody specifically binds to or interferes with at least one selected from the group consisting of SEQ ID NOs:10-16 and 49-126.
- [0049] 42. The method of 29, wherein the tumor is kidney tumor.
- [0050] 43. The method of 42, wherein the composition comprises an antibody that specifically binds to or interferes with the activity of at least one selected from the group consisting of: LRP2, LRP4, and active fragments thereof.
- [0051] 44. The method of 43, wherein the antibody specifically binds to or interferes with at least one selected from the group consisting of SEQ ID NOs:16-18 and 28-111.
- [0052] 45. The method of 29, wherein the tumor is a pancreatic tumor.
- [0053] 46. The method of 45, wherein the composition comprises an antibody that specifically binds to or interferes with the activity of at least one selected from the group consisting of: LRP8 and active fragments thereof.
- [0054] 47. The method of 46, wherein the antibody specifically binds to or interferes with at least one selected from the group consisting of SEQ ID NOs:10-15 and 112-126.
- [0055] 48. The method of 29, wherein the tumor is a thyroid tumor.
- [0056] 49. The method of 48, wherein the composition comprises an antibody that specifically binds to or interferes with the activity of at least one selected from the group consisting of: LRP2, LRP4, and active fragments thereof.
- [0057] 50. The method of 49, wherein the antibody specifically binds to or interferes with at least one selected from the group consisting of SEQ ID NOs:16-18 and 28-111.
- [0058] 51. The method of 29, wherein the tumor is skin cancer.
- [0059] 52. The method of 51, wherein the composition comprises an antibody that specifically binds to or interferes with the activity of at least one selected from the group consisting of: LRP2 (megalin), LRP8, and active fragments thereof.
- [0060] 53. The method of 52, wherein the antibody specifically binds to or interferes with at least one selected from the group consisting of SEQ ID NOs:10-16 and 49-126.

- [0061] 54. The method of 29, wherein the tumor is a brain tumor.
- [0062] 55. The method of 54, wherein the composition comprises an antibody that specifically binds to or interferes with the activity of at least one selected from the group consisting of: LRP2 (megalin) and active fragments thereof.
- [0063] 56. The method of 55, wherein the antibody specifically binds to or interferes with at least one selected from the group consisting of SEQ ID NOs:16 and 49-111.
- [0064] 57. The method of 26, wherein the disease is a degenerative disease.
- [0065] 58. The method of 57, wherein the degenerative disease is a degenerative neural disease.
- [0066] 59. The method of 58, wherein the degenerative neural disease is Alzheimer's disease.
- [0067] 60. The method of 59, wherein the composition comprises an antibody that specifically binds to or interferes with the activity of at least one selected from the group consisting of: LRP8 and active fragments thereof.
- [0068] 61. The method of 60, wherein the antibody specifically binds to or interferes with at least one selected from the group consisting of SEQ ID NOs:10-15 and 112-126.
- [0069] 62. The method of any one of 26 – 61, wherein the composition is administered locally or systemically.
- [0070] 63. The method of any one of 26 – 61, wherein the composition is administered by intravenous, intraperitoneal, intratumor, intralesion, transdermal, intrathecal, subcutaneous, intranasal administration or by inhalation.
- [0071] 64. An isolated polypeptide comprising an amino acid sequence, wherein the amino acid sequence comprises a sequence of at least 6 amino acid residues and is selected from the group consisting of SEQ ID NOs:28-126.
- [0072] 65. An isolated nucleic acid molecule, wherein the nucleic acid molecule comprises a polynucleotide sequence that encodes the polypeptide of 64.
- [0073] 66. A vector comprising the nucleic acid molecule of 65 and a regulatory sequence that regulates the expression of the nucleic acid molecule.
- [0074] 67. A modified cell comprising the nucleic acid molecule of 65 or the vector of 66.
- [0075] 68. An isolated antibody (defined to include active fragments) comprising an antigen binding domain that binds to or interferes with the activity of a polypeptide of 64.

- [0076] 69. The antibody of 68, wherein the antibody is a human antibody.
- [0077] 70. The antibody of 68, wherein the antibody is a humanized antibody.
- [0078] 71. The antibody of 68, wherein the antibody is a monoclonal antibody.
- [0079] 72. The antibody of 68, wherein the antibody is a polyclonal antibody.
- [0080] 73. The antibody of 68, wherein the antibody is a single chain antibody.
- [0081] 74. The antibody of 68, wherein the antibody is a fragment of an immunoglobulin and the fragment binds specifically to an antigen or an epitope.
- [0082] 75. The antibody of 74, wherein the antibody comprises at least one domain selected from the group consisting of a variable region of an immunoglobulin, a constant region of an immunoglobulin, a heavy chain of an immunoglobulin, a light chain of an immunoglobulin and an antigen-binding region of an immunoglobulin.
- [0083] 76. The antibody of 68, wherein the antibody is present in a cell free expression system in which the antibody is expressed.
- [0084] 77. The antibody of 68, wherein the antibody is displayed on a bacteriophage.
- [0085] 78. The antibody of 68, wherein the antibody is produced in a cell and is present in a medium in which the cell is cultured.
- [0086] 79. The antibody of 68, wherein the antibody binds to the polypeptide of 64.
- [0087] 80. The antibody of 68, wherein the antibody binds to a ligand of the polypeptide of 64.
- [0088] 81. The antibody of any one of 68 – 80, wherein the antibody is associated with a cytotoxic or therapeutic agent.
- [0089] 82. The antibody of 81, wherein the antibody is covalently linked to the cytotoxic or therapeutic agent.
- [0090] 83. The antibody of 81, wherein the therapeutic agent is selected from the group consisting of toxins, radioactive isotopes, and chemotherapeutic agents.
- [0091] 84. The antibody of any one of 68 – 83, wherein the antibody is an agonist antibody.
- [0092] 85. The antibody of any one of 68-83, wherein the antibody is an antagonist antibody.
- [0093] 86. A method for detecting a polypeptide in a biological sample comprising:

(a) contacting the biological sample with the antibody of any one of 68 - 78;

and

(b) determining presence of an antibody/polypeptide complex.

[0094] 87. A composition comprising a polypeptide and a modulator, wherein the modulator specifically interferes with the activity or binding of the polypeptide, and wherein the polypeptide is selected from the group consisting of SEQ ID NOS:10-18 and 28-126.

[0095] 88. The composition of 87, wherein the modulator is an antibody.

[0096] 89. The composition of 87, wherein the modulator is a small molecule.

Description of the Figures

[0097] Table 1 shows the polypeptide sequences from SEQ.ID.NO:28 to SEQ.ID.NO:126, and represent the pfam domain fragments from LRP4, LRP8, and megalin).

[0098] Table 2 (SEQ.ID.NO table): column 1 shows an internal designation FP ID number; column 2 shows the nucleotide sequence ID number for the open reading frame ("ORF") nucleotide sequence; column 3 shows the amino acid sequence ID number for the polypeptide sequence; column 4 shows the nucleotide sequence ID number for the entire nucleotide sequence; column 5 shows the classification/gene family; column 6 shows the polypeptide ID number of the source clone or sequence; column 7 shows the nucleotide ID number of the source clone or sequence.

[0099] Table 3 shows the polypeptide alignment of all EGF domains in LRP4, LRP8, and megalin.

[00100] Table 4 shows the polypeptide alignment of all Ldl_recept_a domains in LRP4, LRP8, and megalin.

[00101] Table 5 shows the polypeptide alignment of all Ldl_recept_b domains in LRP4, LRP8, and megalin.

[00102] Table 6 shows the polypeptide alignment of all EGF domains in LRP4.

[00103] Table 7 shows the polypeptide alignment of all Ldl_recept_b domains in LRP4.

[00104] Table 8 shows the polypeptide alignment of all EGF domains in megalin (LRP2).

[00105] Table 9 shows the polypeptide alignment of all Ldl_recept_a domains in megalin (LRP2).

- [00106] Table 10 shows the polypeptide alignment of all Ldl_recept_b domains in megalin (LRP2).
- [00107] Table 11 shows the polypeptide alignment of all Ldl_recept_a domains in LRP8.
- [00108] Table 12 shows the polypeptide alignment of all Ldl_recept_b domains in LRP8.
- [00109] Table 13 shows the pfam domains and coordinates in LRP4; column 1 shows the ID of the polypeptide; column 2 shows the name of the pfam domain; column 3 shows the start coordinate of the pfam domain in the polypeptide; column 4 shows the stop coordinate of the pfam domain in the polypeptide.
- [00110] Table 14 shows the pfam domains and coordinates in megalin (LRP2); column 1 shows the ID of the polypeptide; column 2 shows the name of the pfam domain; column 3 shows the start coordinate of the pfam domain in the polypeptide; column 4 shows the stop coordinate of the pfam domain in the polypeptide.
- [00111] Table 15 shows the pfam domains and coordinates in LRP8; column 1 shows the ID of the polypeptide; column 2 shows the name of the pfam domain; column 3 shows the start coordinate of the pfam domain in the polypeptide; column 4 shows the stop coordinate of the pfam domain in the polypeptide.

DETAILED DESCRIPTION

- [00112] The terms used herein have their ordinary meaning and the meaning given them specifically below.

Definitions

- [00113] The terms used herein have their ordinary meaning and the meaning given them specifically below.

Definitions

- [00114] The terms “polynucleotide,” “nucleotide,” “nucleic acid,” “polynucleic molecule,” “nucleotide molecule,” “nucleic acid molecule,” “nucleic acid sequence,” “polynucleotide sequence,” and “nucleotide sequence” are used interchangeably herein to refer to polymeric forms of nucleotides of any length. The polynucleotides can contain deoxyribonucleotides, ribonucleotides, and/or their analogs or derivatives. For example, nucleic acids can be naturally occurring DNA or RNA, or can be synthetic analogs, as known in the art. The

terms also encompass genomic DNA, genes, gene fragments, exons, introns, regulatory sequences or regulatory elements (such as promoters, enhancers, initiation and termination regions, other control regions, expression regulatory factors, and expression controls), DNA comprising one or more single-nucleotide polymorphisms (SNPs), allelic variants, isolated DNA of any sequence, and cDNA. The terms also encompass mRNA, tRNA, rRNA, ribozymes, splice variants, antisense RNA, antisense conjugates, RNAi, and isolated RNA of any sequence. The terms also encompass recombinant polynucleotides, heterologous polynucleotides, branched polynucleotides, labeled polynucleotides, hybrid DNA/RNA, polynucleotide constructs, vectors comprising the subject nucleic acids, nucleic acid probes, primers, and primer pairs. The polynucleotides can comprise modified nucleic acid molecules, with alterations in the backbone, sugars, or heterocyclic bases, such as methylated nucleic acid molecules, peptide nucleic acids, and nucleic acid molecule analogs, which may be suitable as, for example, probes if they demonstrate superior stability and/or binding affinity under assay conditions. Analogs of purines and pyrimidines, including radiolabeled and fluorescent analogs, are known in the art. The polynucleotides can have any three-dimensional structure, and can perform any function, known or as yet unknown. The terms also encompass single-stranded, double-stranded and triple helical molecules that are either DNA, RNA, or hybrid DNA/RNA and that may encode a full-length gene or a biologically active fragment thereof. Biologically active fragments of polynucleotides can encode the polypeptides herein, as well as anti-sense and RNAi molecules. Thus, the full length polynucleotides herein may be treated with enzymes, such as Dicer, to generate a library of short RNAi fragments which are within the scope of the present invention.

[00115] A “biologically active” entity, or an entity having “biological activity,” is one having structural, regulatory, or biochemical functions of a naturally occurring molecule or any function related to or associated with a metabolic or physiological process. Biologically active polynucleotide fragments are those exhibiting activity similar, but not necessarily identical, to an activity of a polynucleotide of the present invention. The biological activity can include an improved desired activity, or a decreased undesirable activity. For example, an entity demonstrates biological activity when it participates in a molecular interaction with another molecule, or when it has therapeutic value in alleviating

a disease condition, or when it has prophylactic value in inducing an immune response to the molecule, or when it has diagnostic value in determining the presence of the molecule, such as a biologically active fragment of a polynucleotide that can be detected as unique for the polynucleotide molecule, or that can be used as a primer in PCR.

[00116] The term “cDNA” as used herein is intended to include all nucleic acids that share the sequence elements of mature mRNA species, where sequence elements are exons and 3' and 5' non-coding regions. Generally, mRNA species have contiguous exons, the intervening introns having been removed by nuclear RNA splicing to create a continuous open reading frame encoding a protein.

[00117] “Recombinant” as used herein to describe a nucleic acid molecule means a polynucleotide of genomic, cDNA, viral, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation is not associated with all or a portion of the polynucleotide with which it is associated in nature. The term "recombinant" as used with respect to a protein or polypeptide means a polypeptide produced by expression of a recombinant polynucleotide.

[00118] By “selectable marker” is meant a gene which confers a phenotype on a cell expressing the marker, such that the cell can be identified under appropriate conditions. Generally, a selectable marker allows selection of transformed cells based on their ability to thrive in the presence or absence of a chemical or other agent that inhibits an essential cell function. Suitable markers, therefore, include genes coding for proteins which confer drug resistance or sensitivity thereto, impart color to, or change the antigenic characteristics of those cells transfected with a molecule encoding the selectable marker, when the cells are grown in an appropriate selective medium. For example, selectable markers include: cytotoxic markers and drug resistance markers, whereby cells are selected by their ability to grow on media containing one or more of the cytotoxins or drugs; auxotrophic markers by which cells are selected by their ability to grow on defined media with or without particular nutrients or supplements, such as thymidine and hypoxanthine; metabolic markers by which cells are selected for, e.g., their ability to grow on defined media containing the appropriate sugar as the sole carbon source, or markers which confer the ability of cells to form colored colonies on chromogenic substrates or cause cells to fluoresce.

[00119] “Transformation,” as used herein, refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for insertion: for example, transformation by direct uptake, transfection, infection, and the like. For particular methods of transfection, see further below. The exogenous polynucleotide may be maintained as a nonintegrated vector, for example, an episome, or alternatively, may be integrated into the host genome.

[00120] The term “splice variant” refers to all types of RNAs transcribed from a given gene that when processed collectively encode plural protein isoforms. The term “alternative splicing” and related terms refer to all types of RNA processing that lead to expression of plural protein isoforms from a single gene. Some genes are first transcribed as long mRNA precursors that are then shortened by a series of processing steps to produce the mature mRNA molecule. One of these steps is RNA splicing, in which the intron sequences are removed from the mRNA precursor. A cell can splice the primary transcript in different ways, making different “splice variants,” and thereby making different polypeptide chains from the same gene, or from the same mRNA molecule. Splice variants can include, for example, exon insertions, exon extensions, exon truncations, exon deletions, alternatives in the 5' untranslated region and alternatives in the 3' untranslated region.

[00121] “Oligonucleotide” may generally refer to polynucleotides of between about 5 and about 100 nucleotides of single-or double-stranded nucleic acids. For the purposes of this disclosure, there is no upper limit to the length of an oligonucleotide. Oligonucleotides are also known as oligomers or oligos and can be isolated from genes, or chemically synthesized by methods known in the art.

[00122] “Nucleic acid composition” as used herein is a composition comprising a nucleic acid sequence, including one having an open reading frame that encodes a polypeptide and is capable, under appropriate conditions, of being expressed as a polypeptide. The term includes, for example, vectors, including plasmids, cosmids, viral vectors (e.g., retrovirus vectors such as lentivirus, adenovirus, and the like), human, yeast, bacterial, P1-derived artificial chromosomes (HAC's, YAC's, BAC's, PAC's, etc), and mini-chromosomes, *in vitro* host cells, *in vivo* host cells, tissues, organs, allogenic or congenic grafts or transplants, multicellular organisms, and chimeric, genetically modified, or transgenic animals comprising a subject nucleic acid sequence.

[00123] An “isolated,” “purified,” or “substantially isolated” polynucleotide, or a polynucleotide in “substantially pure form,” in “substantially purified form,” in “substantial purity,” or as an “isolate,” is one that is substantially free of the sequences with which it is associated in nature, or other nucleic acid sequences that do not include a sequence or fragment of the subject polynucleotides. By substantially free is meant that less than about 90%, less than about 80%, less than about 70%, less than about 60%, or less than about 50% of the composition is made up of materials other than the isolated polynucleotide. Where at least about 99% of the total macromolecules is the isolated polynucleotide, the polynucleotide is at least about 99% pure, and the composition comprises less than about 1% contaminant.

[00124] As used herein, an “isolated,” “purified” or “substantially isolated” polynucleotide, or a polynucleotide in “substantially pure form,” in “substantially purified form,” in “substantial purity,” or as an “isolate,” also refers to recombinant polynucleotides, modified, degenerate and homologous polynucleotides, and chemically synthesized polynucleotides, which, by virtue of origin or manipulation, are not associated with all or a portion of a polynucleotide with which it is associated in nature, are linked to a polynucleotide other than that to which it is linked in nature, or do not occur in nature. For example, the subject polynucleotides are generally provided as other than on an intact chromosome, and recombinant embodiments are typically flanked by one or more nucleotides not normally associated with the subject polynucleotide on a naturally-occurring chromosome.

[00125] A “gene,” for the purposes of the present disclosure, includes a DNA region encoding a gene product, as well as all DNA regions which regulate the production of the gene product, whether or not such regulatory sequences are adjacent to coding and/or transcribed sequences. Accordingly, a gene includes, but is not necessarily limited to, promoter sequences, terminators, translational regulatory sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, replication origins, matrix attachment sites and locus control regions.

[00126] “Gene expression” refers to the conversion of the information, contained in a gene, into a gene product. A gene product can be the direct transcriptional product of a gene (e.g., mRNA, tRNA, rRNA, antisense RNA, ribozyme, structural RNA or any other type of RNA)

or a protein produced by translation of an mRNA. Gene products also include RNAs which are modified, by processes such as capping, polyadenylation, methylation, and editing, and proteins modified by, for example, methylation, acetylation, phosphorylation, ubiquitination, ADP-ribosylation, myristilation, and glycosylation.

[00127] A “coding sequence” or a sequence which “encodes” a selected polypeptide, is a nucleic acid molecule which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A coding sequence can include, but is not limited to, cDNA from viral, procaryotic or eucaryotic mRNA, genomic DNA sequences from viral (e.g. DNA viruses and retroviruses) or procaryotic DNA, and especially synthetic DNA sequences. A transcription termination sequence may be located 3' to the coding sequence.

[00128] As used herein, the term “antibody” encompasses polyclonal and monoclonal antibody preparations, as well as preparations including hybrid antibodies, altered antibodies, chimeric antibodies and, humanized antibodies, as well as: hybrid (chimeric) antibody molecules (see, for example, Winter et al. (1991); and U.S. Patent No. 4,816,567; F(ab')₂ and F(ab) fragments; Fv molecules (noncovalent heterodimers, see, for example, Inbar et al. (1972); and Ehrlich et al.(1980); single-chain Fv molecules (sFv) (see, e.g., Huston et al. (1980); dimeric and trimeric antibody fragment constructs; minibodies (see, e.g., Pack et al. (1992); Cumber et al. (1992); humanized antibody molecules (see, e.g., Riechmann et al. (1988); Verhoeyan et al.(1988); and, any functional fragments obtained from such molecules, wherein such fragments retain specific-binding.

[00129] As used herein, the term “monoclonal antibody” refers to an antibody composition having a homogeneous antibody population. The term is not limited regarding the species or source of the antibody, nor is it intended to be limited by the manner in which it is made. The term encompasses whole immunoglobulins.

[00130] Methods of making polyclonal and monoclonal antibodies are known in the art. Polyclonal antibodies are generated by immunizing a suitable animal, such as a mouse, rat, rabbit, sheep or goat, with an antigen of interest, such as a stem cell transformed with a gene encoding an antigen. In order to enhance immunogenicity, the antigen can be linked to a

carrier prior to immunization. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Furthermore, the antigen may be conjugated to a bacterial toxoid, such as toxoid from diphtheria, tetanus, cholera, etc., in order to enhance the immunogenicity thereof.

[00131] The terms "polypeptide," "peptide," and "protein," used interchangeably herein, refer to a polymeric form of amino acids of any length, which can include naturally-occurring amino acids, coded and non-coded amino acids, chemically or biochemically modified, derivatized, or designer amino acids, amino acid analogs, peptidomimetics, and depsipeptides, and polypeptides having modified, cyclic, bicyclic, depsicyclic, or depsibicyclic peptide backbones. The term includes fragments of the Ig domains as described herein, single chain protein as well as multimers. The term also includes conjugated proteins, fusion proteins, including, but not limited to, GST fusion proteins, fusion proteins with a heterologous amino acid sequence, fusion proteins with heterologous and homologous leader sequences, fusion proteins with or without N-terminal methionine residues, pegylated proteins, and immunologically tagged proteins. Also included in this term are variations of naturally occurring proteins, where such variations are homologous or substantially similar to the naturally occurring protein, as well as corresponding homologs from different species. Variants of polypeptide sequences include insertions, additions, deletions, or substitutions compared with the subject polypeptides. The term also includes peptide aptamers.

[00132] "Cancer" is herein defined as any abnormal malignant cell or tissue growth, e.g., a tumor. It is characterized by the proliferation of abnormal cells that tend to invade the surrounding tissue and metastasize to new body sites. Cancer encompasses carcinomas, which are cancers of epithelial cells, and are the most common forms of human cancer; carcinomas include squamous cell carcinoma, adenocarcinoma, melanomas, and hepatomas. Cancer also encompasses sarcomas, which are tumors of mesenchymal origin, and includes osteogenic sarcomas, leukemias, and lymphomas. Cancers also encompasses leukemias and lymphomas, and can have one or more than one neoplastic cell type.

[00133] "Treatment," "treating," and the like, as used herein, refer to obtaining a desired pharmacologic and/or physiologic effect, covering any treatment of a disease, pathological condition or disorder in a mammal, including a human. The effect may be prophylactic in terms of completely or partially preventing a disorder or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disorder and/or adverse affect attributable to the disorder. That is, "treatment" includes (1) preventing the disorder from occurring or recurring in a subject who may be predisposed to the disorder but has not yet been diagnosed as having it, (2) inhibiting the disorder, such as arresting its development, (3) stopping or terminating the disorder or at least symptoms associated therewith, so that the host no longer suffers from the disorder or its symptoms, such as causing regression of the disorder or its symptoms, for example, by restoring or repairing a lost, missing or defective function, or stimulating an inefficient process, or (4) relieving, alleviating, or ameliorating the disorder, or symptoms associated therewith, where ameliorating is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, such as inflammation, pain, and/or tumor size.

[00134] The term "disease" or "diseases" in a subject or an animal as used herein include disease, disorder, conditions, syndrome or infections in the subject or animal.

[00135] By "fragment" is intended a polypeptide, e.g., Ig domains, consisting of only a part of the intact full-length polypeptide sequence and structure. The fragment can include a C-terminal deletion an N-terminal deletion, and/or an internal deletion of the native polypeptide. A fragment of a protein will generally include at least about 5-10 contiguous amino acid residues of the full-length molecule, preferably at least about 15-25 contiguous amino acid residues of the full-length molecule, and most preferably at least about 20-50 or more contiguous amino acid residues of the full-length molecule, or any integer between 5 amino acids and the full-length sequence.

[00136] As noted above, a "biologically active" entity, or an entity having "biological activity," is one having structural, regulatory, or biochemical functions of a naturally occurring molecule or any function related to or associated with a metabolic or physiological process. Biologically active polypeptide fragments are those exhibiting activity similar, but not necessarily identical, to an activity of a polypeptide of the present invention. The biological activity can include an improved desired activity, or a decreased

undesirable activity. For example, an entity demonstrates biological activity when it participates in a molecular interaction with another molecule, or when it has therapeutic value in alleviating a disease condition, or when it has prophylactic value in inducing an immune response to the molecule, or when it has diagnostic value in determining the presence of the molecule. A biologically active polypeptide or fragment thereof includes one that can participate in a biological reaction, for example, as a transcription factor that combines with other transcription factors for initiation of transcription, or that can serve as an epitope or immunogen to stimulate an immune response, such as production of antibodies, or that can transport molecules into or out of cells, or that can perform a catalytic activity, for example polymerization or nuclease activity, or that can participate in signal transduction by binding to receptors, proteins, or nucleic acids, activating enzymes or substrates.

[00137] A “signal peptide,” or a “leader sequence,” comprises a sequence of amino acid residues, typically, at the N terminus of a polypeptide, which directs the intracellular trafficking of the polypeptide. Polypeptides that contain a signal peptide or leader sequence typically also contain a signal peptide or leader sequence cleavage site. Such polypeptides, after cleavage at the cleavage sites, generate mature polypeptides, for example, after extracellular secretion or after being directed to the appropriate intracellular compartment.

[00138] An “isolated,” “purified,” or “substantially isolated” polypeptide, or a polypeptide in “substantially pure form,” in “substantially purified form,” in “substantial purity,” or as an “isolate,” is one that is substantially free of the materials with which it is associated in nature or other polypeptide sequences that do not include a sequence or fragment of the subject polypeptides. By substantially free is meant that less than about 90%, less than about 80%, less than about 70%, less than about 60%, or less than about 50% of the composition is made up of materials other than the isolated polypeptide. Where at least about 99% of the total macromolecules is the isolated polypeptide, the polypeptide is at least about 99% pure, and the composition comprises less than about 1% contaminant.

[00139] Detection methods of the invention can be qualitative or quantitative. Thus, as used herein, the terms “detection,” “identification,” “determination,” and the like, refer to both qualitative and quantitative determinations, and include “measuring.” For example, detection methods include methods for detecting the presence and/or level of polynucleotide

or polypeptide in a biological sample, and methods for detecting the presence and/or level of biological activity of polynucleotide or polypeptide in a sample.

[00140] A “nucleic acid hybridization reaction” is one in which single strands of DNA or RNA randomly collide with one another, and bind to each other only when their nucleotide sequences have some degree of complementarity. The solvent and temperature conditions can be varied in the reactions to modulate the extent to which the molecules can bind to one another. Hybridization reactions can be performed under different conditions of “stringency.” The “stringency” of a hybridization reaction as used herein refers to the conditions (e.g., solvent and temperature conditions) under which two nucleic acid strands will either pair or fail to pair to form a “hybrid” helix.

[00141] A “buffer” is a system that tends to resist change in pH when a given increment of hydrogen ion or hydroxide ion is added. Buffered solutions contain conjugate acid-base pairs. Any conventional buffer can be used with the inventions herein including but not limited to, for example, Tris, phosphate, imidazole, and bicarbonate.

[00142] “Sequence similarity,” “sequence homology,” “homology,” “sequence identity,” and “percent sequence identity,” used interchangeably herein, describe the degree of relatedness between two polynucleotide or polypeptide sequences. In general, “identity” means the exact match-up of two or more nucleotide sequences or two or more amino acid sequences, where the nucleotide or amino acids being compared are the same. Also, in general, “similarity” or “homology” means the exact match-up of two or more nucleotide sequences or two or more amino acid sequences, where the nucleotide or amino acids being compared are either the same or possess similar chemical and/or physical properties. The terms also refer to the percentage of the “aligned” bases (for the polynucleotides) or amino acid residues (for the polypeptides) that are identical when the sequences are aligned. Sequences can be aligned in a number of different ways and sequence similarity can be determined in a number of different ways. For example, the bases or amino acid residues of one sequence can be aligned to a gap in the other sequence, or they can be aligned only to another base or amino acid residue in the other sequence. A gap can range anywhere from one nucleotide, base, or amino acid residue to multiple exons in length, up to any number of nucleotides or amino acid residues. Further, sequences can be aligned such that nucleotides (or bases)

align with nucleotides, nucleotides align with amino acid residues, or amino acid residues align with amino acid residues.

[00143] The term “binds specifically,” in the context of antibody binding, refers to high avidity and/or high affinity binding of an antibody to a specific polypeptide, or more accurately, to an epitope of a specific polypeptide. Antibody binding to such epitope on a polypeptide can be stronger than binding of the same antibody to any other epitopes, particularly other epitopes that can be present in molecules in association with, or in the same sample as the polypeptide of interest. For example, when an antibody binds more strongly to one epitope than to another, adjusting the binding conditions can result in antibody binding almost exclusively to the specific epitope and not to any other epitopes on the same polypeptide, and not to any other polypeptide, which does not comprise the epitope. Antibodies that bind specifically to a subject polypeptide may be capable of binding other polypeptides at a weak, yet detectable, level (e.g., 10% or less of the binding shown to the polypeptide of interest). Such weak binding, or background binding, is readily discernible from the specific antibody binding to a subject polypeptide, e.g., by use of appropriate controls. In general, antibodies of the invention bind to a specific polypeptide with a binding affinity of 10^{-7} M or greater (e.g., 10^{-8} M, 10^{-9} M, 10^{-10} , 10^{-11} , etc.).

[00144] The term “host cell” includes an individual cell, cell line, cell culture, or *in vivo* cell, which can be or has been a recipient of any polynucleotides or polypeptides of the invention, for example, a recombinant vector, an isolated polynucleotide, antibody or fusion protein. Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology, physiology, or in total DNA, RNA, or polypeptide complement) to the original parent cell due to natural, accidental, or deliberate mutation and/or change. Host cells can be prokaryotic or eukaryotic, including mammalian, insect, amphibian, reptile, crustacean, avian, fish, plant and fungal cells. A host cell includes cells transformed, transfected, transduced, or infected *in vivo* or *in vitro* with a polynucleotide of the invention, for example, a recombinant vector. A host cell which comprises a recombinant vector of the invention may be called a “recombinant host cell.”

[00145] “Biological sample,” “patient sample,” “clinical sample,” “sample,” or “biological specimen,” used interchangeably herein, encompasses a variety of sample types obtained from an individual, including biological fluids such as blood, serum, plasma, urine,

cerebrospinal fluid, tears, saliva, lymph, dialysis fluid, lavage fluid, semen, and other liquid samples or tissues of biological origin. It includes tissue samples and tissue cultures or cells derived therefrom and the progeny thereof, including cells in culture, cell supernatants, and cell lysates. It includes organ or tissue culture derived fluids, tissue biopsy samples, tumor biopsy samples, stool samples, and fluids extracted from physiological tissues. Cells dissociated from solid tissues, tissue sections, and cell lysates are included. The definition also includes samples that have been manipulated in any way after their procurement, such as by treatment with reagents, solubilization, or enrichment for certain components, such as polynucleotides or polypeptides. Also included in the term are derivatives and fractions of biological samples. A biological sample can be used in a diagnostic, monitoring, or screening assay.

[00146] The terms “linked,” “link,” “linkage,” and “linking,” may be used interchangeably herein, and refer to covalent and non-covalent conjugation between a molecule and an agent. For example, in certain embodiments of the invention, a molecule, such as an antibody, can be conjugated to an agent, such as a cytotoxic compound. Methods of preparation of linkers and cytotoxic compounds are known in the art, and can be found, for example, in PCT publication WO 03/061694. Cytotoxic compounds of the invention include, for example, capecitabine, carboplatin, chlorambucil, cisplatin, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, doxorubicin, epirubicin, estramustine, etoposide phosphate, fludarabine, fluorouracil, 5-FU, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, eucovorin, meclorethamine nitrogen mustard, methotrexate, mitomycin C, mitoxantrone, oxaliplatin, paclitaxel, tamoxifen, topotecan, vinblastine, vincristine, and vinorelbine.

[00147] The terms “individual,” “host,” “patient,” and “subject,” used interchangeably herein, refer to a mammal, including, but not limited to, murines, simians, humans, felines, canines, equines, bovines, porcines, ovines, caprines, mammalian farm animals, mammalian sport animals, and mammalian pets. “Mammals” or “mammalian,” are used broadly to describe organisms which are within the class mammalia, including the orders carnivore (*e.g.*, dogs and cats), rodentia (*e.g.*, mice, guinea pigs, and rats), and other mammals, including cattle, goats, sheep, cows, horses, rabbits, and pigs, and primates (*e.g.*, humans, chimpanzees, and monkeys).

[00148] The terms “agent,” “substance,” “modulator,” and “compound” are used interchangeably herein. These terms refer to a substance that binds to or modulates a level or activity of a subject polypeptide or a level of mRNA encoding a subject protein or nucleic acid, or that modulates the activity of a cell containing the subject protein or nucleic acid. Where the agent modulates a level of mRNA encoding a subject protein, agents include ribozymes, antisense, and RNAi molecules. Where the agent is a substance that modulates a level of activity of a subject polypeptide, agents include antibodies specific for the subject polypeptide, peptide aptamers, small molecules, agents that bind a ligand-binding site in a subject polypeptide, and the like. Antibody agents include antibodies that specifically bind a subject polypeptide and activate the polypeptide, such as receptor-ligand binding that initiates signal transduction; antibodies that specifically bind a subject polypeptide and inhibit binding of another molecule to the polypeptide, thus preventing activation of a signal transduction pathway; antibodies that bind a subject polypeptide to modulate transcription; antibodies that bind a subject polypeptide to modulate translation; as well as antibodies that bind a subject polypeptide on the surface of a cell to initiate antibody-dependent cytotoxicity (“ADCC”) or to initiate cell killing or cell growth. Small molecule agents include those that bind the polypeptide to modulate activity of the polypeptide or cell containing the polypeptide in a similar fashion. The term “agent” also refers to substances that modulate a condition or disorder associated with a subject polynucleotide or polypeptide. Such agents include subject polynucleotides themselves, subject polypeptides themselves, and the like. Agents may be chosen from amongst candidate agents, as defined below.

[00149] The terms “candidate agent,” “subject agent,” or “test agent,” used interchangeably herein, encompass numerous chemical classes, typically synthetic, semi-synthetic, or naturally occurring inorganic or organic molecules, small molecules, or macromolecular complexes. Candidate agents can be small organic compounds having a molecular weight of more than about 50 and less than about 2,500 daltons. Candidate agents can comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and can include at least an amine, carbonyl, hydroxyl or carboxyl group, and can contain at least two of the functional chemical groups. The candidate agents can comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures

substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules, including oligonucleotides, polynucleotides, and fragments thereof, depsipeptides, polypeptides and fragments thereof, oligosaccharides, polysaccharides and fragments thereof, lipids, fatty acids, steroids, purines, pyrimidines, derivatives thereof, structural analogs, modified nucleic acids, modified, derivatized or designer amino acids, or combinations thereof.

- [00150] An “agent which modulates a biological activity of a subject polypeptide,” as used herein, describes any substance, synthetic, semi-synthetic, or natural, organic or inorganic, small molecule or macromolecular, pharmaceutical or protein, with the capability of altering a biological activity of a subject polypeptide or of a fragment thereof, as described herein. Generally, a plurality of assay mixtures is run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection. The biological activity can be measured using any assay known in the art.
- [00151] An agent which modulates a biological activity of a subject polypeptide increases or decreases the activity at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 50%, at least about 100%, or at least about 2-fold, at least about 5-fold, or at least about 10-fold or more when compared to a suitable control.
- [00152] The term “agonist” refers to a substance that mimics the function of an active molecule. Agonists include, but are not limited to, drugs, hormones, antibodies, and neurotransmitters, as well as analogues and fragments thereof.
- [00153] The term “antagonist” refers to a molecule that competes for the binding sites of an agonist, but does not induce an active response. Antagonists include, but are not limited to, drugs, hormones, antibodies, and neurotransmitters, as well as analogues and fragments thereof.
- [00154] The term “receptor” refers to a polypeptide that binds to a specific extracellular molecule and may initiate a cellular response.
- [00155] The term “ligand” refers to any molecule that binds to a specific site on another molecule.

[00156] The term “modulate” encompasses an increase or a decrease, a stimulation, inhibition, or blockage in the measured activity when compared to a suitable control. “Modulation” of expression levels includes increasing the level and decreasing the level of an mRNA or polypeptide encoded by a polynucleotide of the invention when compared to a control lacking the agent being tested. In some embodiments, agents of particular interest are those which inhibit a biological activity of a subject polypeptide, and/or which reduce a level of a subject polypeptide in a cell, and/or which reduce a level of a subject mRNA in a cell and/or which reduce the release of a subject polypeptide from a eukaryotic cell. In other embodiments, agents of interest are those that increase a biological activity of a subject polypeptide, and/or which increase a level of a subject polypeptide in a cell, and/or which increase a level of a subject mRNA in a cell and/or which increase the release of a subject polypeptide from a eukaryotic cell.

[00157] An agent that “modulates the level of expression of a nucleic acid” in a cell is one that brings about an increase or decrease of at least about 1.25-fold, at least about 1.5-fold, at least about 2-fold, at least about 5-fold, at least about 10-fold, or more in the level (i.e., an amount) of mRNA and/or polypeptide following cell contact with a candidate agent compared to a control lacking the agent.

[00158] “Modulating a level of active subject polypeptide” includes increasing or decreasing activity of a subject polypeptide; increasing or decreasing a level of active polypeptide protein; increasing or decreasing a level of mRNA encoding active subject polypeptide, and increasing or decreasing the release of subject polypeptide for a eukaryotic cell. In some embodiments, an agent is a subject polypeptide, where the subject polypeptide itself is administered to an individual. In some embodiments, an agent is an antibody specific for a subject polypeptide. In some embodiments, an agent is a chemical compound such as a small molecule that may be useful as an orally available drug. Such modulation includes the recruitment of other molecules that directly effect the modulation. For example, an antibody that modulates the activity of a subject polypeptide that is a receptor on a cell surface may bind to the receptor and fix complement, activating the complement cascade and resulting in lysis of the cell.

[00159] The term “over-expressed” refers to a state wherein there exists any measurable increase over normal or baseline levels. For example, a molecule that is over-expressed in a

disorder is one that is manifest in a measurably higher level compared to levels in the absence of the disorder.

[00160] An “anti-cancer molecule” is a molecule that can diminish, eliminate, or prevent the effects of cancer. It includes pharmaceuticals and antibodies.

[00161] A “promoter” is a region of DNA that binds RNA polymerase before initiating the transcription of DNA into RNA. The nucleotide at which transcription begins is designated +1; nucleotides are numbered from this reference point. Negative numbers indicate upstream nucleotides and positive numbers indicate downstream nucleotides. The promoter directs the RNA polymerase to bind to DNA, to open the DNA helix, and to begin RNA synthesis. Some promoters are “constitutive,” and direct transcription in the absence of regulatory influences. Some promoters are “tissue specific,” and initiate transcription exclusively or selectively in one or a few tissue types. Some promoters are “inducible,” and effect gene transcription under the influence of an inducer. Induction can occur, e.g., as the result of a physiologic response, a response to outside signals, or as the result of artificial manipulation.

[00162] “Operably linked” refers to an arrangement of elements wherein the components so described are configured so as to perform their desired function. Thus, a given promoter operably linked to a coding sequence is capable of effecting the expression of the coding sequence when the proper transcription factors, etc., are present. The promoter need not be contiguous with the coding sequence, so long as it functions to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can be present between the promoter sequence and the coding sequence, as can translated introns, and the promoter sequence can still be considered “operably linked” to the coding sequence.

[00163] A “therapeutic factor” encoded by a first heterologous nucleic acid sequence of a modified mesenchymal cell is a factor, excluding a cell survival factor (Mangi et al., 2003; WO 03/073998), that is preventative, palliative, curative, or otherwise useful in treating or ameliorating, or preventing the recurrence of a disease, disorder, syndrome or condition, and is not an anti-cancer agent.

[00164] “Treatment,” “treating,” and the like, as used herein, refer to obtaining a desired pharmacologic and/or physiologic effect, covering any treatment of a pathological condition or disorder in a mammal, including a human. The effect may be prophylactic in terms of

completely or partially preventing a disorder or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disorder and/or adverse affect attributable to the disorder. That is, "treatment" includes (1) preventing the disorder from occurring or recurring in a subject who may be predisposed to the disorder but has not yet been diagnosed as having it, (2) inhibiting the disorder, such as arresting its development, (3) stopping or terminating the disorder or at least symptoms associated therewith, so that the host no longer suffers from the disorder or its symptoms, such as causing regression of the disorder or its symptoms, for example, by restoring or repairing a lost, missing or defective function, or stimulating an inefficient process, or (4) relieving, alleviating, or ameliorating the disorder, or symptoms associated therewith, where ameliorating is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, such as inflammation, pain, and/or tumor size.

[00165] A "pharmaceutically acceptable carrier," "pharmaceutically acceptable diluent," or "pharmaceutically acceptable excipient," or "pharmaceutically acceptable vehicle," used interchangeably herein, refer to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any conventional type. A pharmaceutically acceptable carrier is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the carrier for a formulation containing polypeptides would not normally include oxidizing agents and other compounds that are known to be deleterious to polypeptides. Suitable carriers include, but are not limited to, water, dextrose, glycerol, saline, ethanol, and combinations thereof. The carrier can contain additional agents such as wetting or emulsifying agents, pH buffering agents, or adjuvants which enhance the effectiveness of the formulation. Adjuvants of the invention include, but are not limited to Freund's, Montanide ISA Adjuvants [Seppic, Paris, France], Ribi's Adjuvants (Ribi ImmunoChem Research, Inc., Hamilton, MT), Hunter's TiterMax (CytRx Corp., Norcross, GA), Aluminum Salt Adjuvants (Alhydrogel - Superfos of Denmark/Accurate Chemical and Scientific Co., Westbury, NY), Nitrocellulose-Adsorbed Protein, Encapsulated Antigens, and Gerbu Adjuvant (Gerbu Biotechnik GmbH, Gaiberg, Germany/C-C Biotech, Poway, CA). Topical carriers include liquid petroleum, isopropyl palmitate, polyethylene glycol, ethanol (95%), polyoxyethylene monolaurate (5%) in water, or sodium lauryl sulfate (5%)

in water. Other materials such as anti-oxidants, humectants, viscosity stabilizers, and similar agents can be added as necessary. Percutaneous penetration enhancers such as Azone can also be included.

[00166] “Pharmaceutically acceptable salts” include the acid addition salts (formed with the free amino groups of the polypeptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, mandelic, oxalic, and tartaric. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, and histidine.

[00167] Compositions for oral administration can form solutions, suspensions, tablets, pills, capsules, sustained release formulations, oral rinses, or powders.

[00168] The term “unit dosage form,” as used herein, refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of compounds of the present invention calculated in an “effective amount,” that is, a dosage sufficient to produce the desired result or effect in association with a pharmaceutically acceptable carrier. The specifications for the novel unit dosage forms of the present invention depend on the particular compound employed, the host, and the effect to be achieved, as well as the pharmacodynamics associated with each compound in the host.

[00169]

[00170] Screening and Diagnostic Methods

[00171] 1. Identifying Biological Molecules that Interact with a Polypeptide

[00172] Formation of a binding complex between a subject polypeptide and an interacting polypeptide or other macromolecule (e.g., DNA, RNA, lipids, polysaccharides, and the like) can be detected using any known method. Suitable methods include: a yeast two-hybrid system (Zhu et al., 1997; Fields and Song, 1989; U.S. Pat. No. 5,283,173; Chien et al. 1991); a mammalian cell two-hybrid method; a fluorescence resonance energy transfer (FRET) assay; a bioluminescence resonance energy transfer (BRET) assay; a fluorescence quenching assay; a fluorescence anisotropy assay (Jameson and Sawyer, 1995); an

immunological assay; and an assay involving binding of a detectably labeled protein to an immobilized protein.

2. Detecting mRNA Levels and Monitoring Gene Expression

[00173] The present invention provides methods for detecting the presence of mRNA in a biological sample. The methods can be used, for example, to assess whether a test compound affects gene expression, either directly or indirectly. The present invention provides diagnostic methods to compare the abundance of a nucleic acid with that of a control value, either qualitatively or quantitatively, and to relate the value to a normal or abnormal expression pattern.

[00174] Methods of measuring mRNA levels are known in the art, as described in for example, WO 97/27317. These methods generally comprise contacting a sample with a polynucleotide of the invention under conditions that allow hybridization and detecting hybridization, if any, as an indication of the presence of the polynucleotide of interest. Detection can be accomplished by any known method, including, but not limited to, *in situ* hybridization, PCR, RT-PCR, and "Northern" or RNA blotting, or combinations of such techniques, using a suitably labeled subject polynucleotide. A common method employed is use of microarrays which can be purchased or customized, for example, through conventional vendors such as Affymetrix.

3. Detecting and Monitoring Polypeptide Presence and Biological Activity

[00175] The present invention provides methods for detecting the presence and/or biological activity of a subject polypeptide in a biological sample. The assay used will be appropriate to the biological activity of the particular polypeptide. Thus, e.g., where the biological activity is binding to a second macromolecule, the assay detects protein-protein binding, protein-DNA binding, protein-carbohydrate binding, or protein-lipid binding, as appropriate, using well known assays. Where the biological activity is signal transduction (e.g., transmission of a signal from outside the cell to inside the cell) or transport, an appropriate assay is used, such as measurement of intracellular calcium ion concentration, measurement of membrane conductance changes, or measurement of intracellular potassium ion concentration.

[00176] The present invention also provides methods for detecting the presence or measuring the level of a normal or abnormal polypeptide in a biological sample using a specific antibody. The methods generally comprise contacting the sample with a specific antibody and detecting binding between the antibody and molecules of the sample. Specific antibody binding, when compared to a suitable control, is an indication that a polypeptide of interest is present in the sample.

[00177] A variety of methods to detect specific antibody-antigen interactions are known in the art, e.g., standard immunohistological methods, immunoprecipitation, enzyme immunoassay, and radioimmunoassay. Briefly, antibodies are added to a cell sample, and incubated for a period of time sufficient to allow binding to the epitope, usually at least about 10 minutes. The antibody may be labeled with radioisotopes, enzymes, fluorescers, chemilumescers, or other labels for direct detection.. Alternatively, specific-binding pairs may be used, involving, e.g., a second stage antibody or reagent that is detectably-labeled, as described above. Such reagents and their methods of use are well known in the art.

4. Modulating mRNA and Peptides in Biological Samples

[00178] The present invention provides screening methods for identifying agents that modulate the level of a mRNA molecule of the invention, agents that modulate the level of a polypeptide of the invention, and agents that modulate the biological activity of a polypeptide of the invention. In some embodiments, the assay is cell-free; in others, it is cell-based. Where the screening assay is a binding assay, one or more of the molecules can be joined to a label, where the label can directly or indirectly provide a detectable signal.

[00179] In these embodiments, the candidate agent is combined with a cell possessing a polynucleotide transcriptional regulatory element operably linked to a polypeptide-coding sequence of interest, e.g., a subject cDNA or its genomic component; and determining the agent's effect on polynucleotide expression, as measured, for example by the level of mRNA, polypeptide, or fusion polypeptide

[00180] In other embodiments, for example, a recombinant vector can comprise an isolated polynucleotide transcriptional regulatory sequence, such as a promoter sequence, operably linked to a reporter gene (e.g., β -galactosidase, CAT, luciferase, or other gene that can be

easily assayed for expression). In these embodiments, the method for identifying an agent that modulates a level of expression of a polynucleotide in a cell comprises combining a candidate agent with a cell comprising a transcriptional regulatory element operably linked to a reporter gene; and determining the effect of said agent on reporter gene expression.

[00181] Known methods of measuring mRNA levels can be used to identify agents that modulate mRNA levels, including, but not limited to, PCR with detectably-labeled primers. Similarly, agents that modulate polypeptide levels can be identified using standard methods for determining polypeptide levels, including, but not limited to an immunoassay such as ELISA with detectably-labeled antibodies.

[00182] A wide variety of cell-based assays can also be used to identify agents that modulate eukaryotic or prokaryotic mRNA and/or polypeptide levels. Examples include transformed cells that over-express a cDNA construct and cells transformed with a polynucleotide of interest associated with an endogenously-associated promoter operably linked to a reporter gene. Expression levels are measured and compared in the test and control samples.

[00183] Accordingly, the present invention provides a method for identifying an agent, particularly a biologically active agent that modulates the level of expression of a nucleic acid in a cell, the method comprising: combining a candidate agent to be tested with a cell comprising a nucleic acid that encodes the polypeptide, and determining the agent's effect on polypeptide expression.

[00184] Agents that decrease a biological activity can find use in treating disorders associated with the biological activity of the molecule. Alternatively, some embodiments will detect agents that increase a biological activity. Agents that increase a biological activity of a molecule of the invention can find use in treating disorders associated with a deficiency in the biological activity.

[00185] A variety of different candidate agents can be screened by the above methods. Candidate agents encompass numerous chemical classes, as described above.

[00186] Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. Numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. For example, random peptide libraries

obtained by yeast two-hybrid screens (Xu et al., 1997), phage libraries (Hoogenboom et al., 1998), or chemically generated libraries. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced, including antibodies produced upon immunization of an animal with subject polypeptides, or fragments thereof, or with the encoding polynucleotides. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and can be used to produce combinatorial libraries. Further, known pharmacological agents can be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, and amidification, etc, to produce structural analogs.

5. Kits

[00187] The present invention provides methods for diagnosing disease states based on the detected presence and/or level of polynucleotide or polypeptide in a biological sample, and/or the detected presence and/or level of biological activity of the polynucleotide or polypeptide. These detection methods can be provided as part of a kit. Thus, the invention further provides kits for detecting the presence and/or a level of a polynucleotide or polypeptide in a biological sample and/or or the detected presence and/or level of biological activity of the polynucleotide or polypeptide.

[00188] Where the kit provides for polypeptide detection, it can include one or more specific antibodies. In some embodiments, the antibody specific to the polypeptide is detectably labeled. In other embodiments, the antibody specific to the polypeptide is not labeled; instead, a second, detectably-labeled antibody is provided that binds to the specific antibody. The kit may further include blocking reagents, buffers, and reagents for developing and/or detecting the detectable marker. The kit may further include instructions for use, controls, and interpretive information.

[00189] The present invention provides for kits with unit doses of an active agent. In some embodiments, the agent is provided in oral or injectable doses. Such kits will comprise containers containing the unit doses and an informational package insert describing the use and attendant benefits of the drugs in treating a condition of interest.

Therapeutic Compositions

[00190] The invention further provides agents identified using a screening assay of the invention, and compositions comprising the agents, subject polypeptides, subject polynucleotides, modulators thereof including antibodies, recombinant vectors, and/or host cells, including pharmaceutical compositions containing such in a pharmaceutically acceptable carrier or excipient for therapeutic administration. The subject compositions can be formulated using well-known reagents and methods. These compositions can include a buffer, which is selected according to the desired use of the agent, polypeptide, polynucleotide, recombinant vector, or host cell, and can also include other substances appropriate to the intended use. Those skilled in the art can readily select an appropriate buffer, a wide variety of which are known in the art, suitable for an intended use.

1. Excipients and Formulations

[00191] In some embodiments, compositions are provided in formulation with pharmaceutically acceptable excipients, a wide variety of which are known in the art (Gennaro, 2000; Ansel et al., 1999; Kibbe et al., 2000). Pharmaceutically acceptable excipients, such as vehicles, adjuvants, carriers or diluents, are readily available to the public. Moreover, pharmaceutically acceptable auxiliary substances, such as pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents and the like, are readily available to the public.

[00192] In pharmaceutical dosage forms, the compositions of the invention can be administered in the form of their pharmaceutically acceptable salts, or they can also be used alone or in appropriate association, as well as in combination, with other pharmaceutically active compounds. The subject compositions are formulated in accordance to the mode of potential administration. Administration of the agents can be achieved in various ways, including oral, buccal, nasal, rectal, parenteral, intraperitoneal, intradermal, transdermal, subcutaneous, intravenous, intra-arterial, intracardiac, intraventricular, intracranial, intratracheal, and intrathecal administration, etc., or otherwise by implantation or inhalation. Thus, the subject compositions can be formulated into preparations in solid, semi-solid,

liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants and aerosols. The following methods and excipients are merely exemplary and are in no way limiting.

[00193] Compositions for oral administration can form solutions, suspensions, tablets, pills, granules, capsules, sustained release formulations, oral rinses, or powders. For oral preparations, the agents, polynucleotides, and polypeptides can be used alone or in combination with appropriate additives, for example, with conventional additives, such as lactose, mannitol, corn starch, or potato starch; with binders, such as crystalline cellulose, cellulose derivatives, acacia, corn starch, or gelatins; with disintegrators, such as corn starch, potato starch, or sodium carboxymethylcellulose; with lubricants, such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents, preservatives, and flavoring agents.

[00194] Suitable excipient vehicles are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired, the vehicle can contain minor amounts of auxiliary substances such as wetting or emulsifying agents or pH buffering agents. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in the art (Remington, 1985). The composition or formulation to be administered will, in any event, contain a quantity of the agent adequate to achieve the desired state in the subject being treated.

[00195] The agents, polynucleotides, and polypeptides can be formulated into preparations for injection by dissolving, suspending or emulsifying them in an aqueous or nonaqueous solvent, such as vegetable or other similar oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives. Other formulations for oral or parenteral delivery can also be used, as conventional in the art

[00196] The antibodies, agents, polynucleotides, and polypeptides can be utilized in aerosol formulation to be administered via inhalation. The compounds of the present invention can be formulated into pressurized acceptable propellants such as dichlorodifluoromethane, propane, nitrogen, and the like. Further, the agent, polynucleotides, or polypeptide

composition may be converted to powder form for administration intranasally or by inhalation, as conventional in the art.

[00197] Furthermore, the agents can be made into suppositories by mixing with a variety of bases such as emulsifying bases or water-soluble bases. The compounds of the present invention can be administered rectally via a suppository. The suppository can include vehicles such as cocoa butter, carbowaxes and polyethylene glycols, which melt at body temperature, yet are solidified at room temperature.

[00198] A polynucleotide, polypeptide, or other modulator, can also be introduced into tissues or host cells by other routes, such as viral infection, microinjection, or vesicle fusion. For example, expression vectors can be used to introduce nucleic acid compositions into a cell as described above. Further, jet injection can be used for intramuscular administration (Furth et al., 1992). The DNA can be coated onto gold microparticles, and delivered intradermally by a particle bombardment device, or "gene gun" as described in the literature (Tang et al., 1992), where gold microprojectiles are coated with the DNA, then bombarded into skin cells.

[00199] Unit dosage forms for oral or rectal administration such as syrups, elixirs, and suspensions can be provided wherein each dosage unit, for example, teaspoonful, tablespoonful, tablet, or suppository, contains a predetermined amount of the composition containing one or more agents. Similarly, unit dosage forms for injection or intravenous administration can comprise the agent(s) in a composition as a solution in sterile water, normal saline or another pharmaceutically acceptable carrier.

2. Active Agents (or Modulators)

[00200] The nucleic acid, polypeptide, and modulator compositions of the subject invention find use as therapeutic agents in situations where one wishes to modulate an activity of a subject polypeptide in a host, particularly the activity of the subject polypeptides, or to provide or inhibit the activity at a particular anatomical site. Thus, the compositions are useful in treating disorders associated with an activity of a subject polypeptide. The following provides further details of active agents of the present invention.

a) Antisense Oligonucleotides

[00201] In certain embodiments of the invention, the active agent is an agent that modulates, and generally decreases or down regulates, the expression of sFRP-1 or sFRP-3 in a host, i.e., antisense molecules. Anti-sense reagents include antisense oligonucleotides (ODN), i.e., synthetic ODN having chemical modifications from native nucleic acids, or nucleic acid constructs that express such anti-sense molecules as RNA. The antisense sequence is complementary to the mRNA of the targeted gene, and inhibits expression of the targeted gene products. Antisense molecules inhibit gene expression through various mechanisms, e.g., by reducing the amount of mRNA available for translation, through activation of RNase H, or steric hindrance. One or a combination of antisense molecules can be administered, where a combination can comprise multiple different sequences.

[00202] Antisense molecules can be produced by expression of all or a part of the target gene sequence in an appropriate vector, where the transcriptional initiation is oriented such that an antisense strand is produced as an RNA molecule. Alternatively, the antisense molecule is a synthetic oligonucleotide. Antisense oligonucleotides can be chemically synthesized by methods known in the art (Wagner et al., 1993; Milligan et al., 1993). Antisense oligonucleotides will generally be at least about 7, at least about 12, or at least about 20 nucleotides in length, and not more than about 500, not more than about 50, or not more than about 35 nucleotides in length, where the length is governed by efficiency of inhibition, and specificity, including absence of cross-reactivity, and the like. Short oligonucleotides, of from about 7 to about 8 bases in length, can be strong and selective inhibitors of gene expression (Wagner et al., 1996).

[00203] As an alternative to anti-sense inhibitors, catalytic nucleic acid compounds, e.g., ribozymes, or anti-sense conjugates can be used to inhibit gene expression. Ribozymes can be synthesized *in vitro* and administered to the patient, or can be encoded in an expression vector, from which the ribozyme is synthesized in the targeted cell (WO 9523225; Beigelman et al., 1995). Examples of oligonucleotides with catalytic activity are described in WO 9506764. Conjugates of anti-sense ODN with a metal complex, e.g., terpyridyl Cu(II), capable of mediating mRNA hydrolysis are described in Bashkin *et al.*, 1995.

b) Interfering RNA

[00204] In some embodiments, the active agent is an interfering RNA (RNAi), including dsRNAi. RNA interference provides a method of silencing eukaryotic genes. Use of RNAi

to reduce a level of a particular mRNA and/or protein is based on the interfering properties of double-stranded RNA derived from the coding regions of a gene. The technique is an efficient high-throughput method for disrupting gene function (O'Neil, 2001). RNAi can also help identify the biochemical mode of action of a drug and to identify other genes encoding products that can respond or interact with specific compounds.

[00205] In one embodiment of the invention, complementary sense and antisense RNAs derived from a substantial portion of the subject polynucleotide are synthesized *in vitro*. The resulting sense and antisense RNAs are annealed in an injection buffer, and the double-stranded RNA injected or otherwise introduced into the subject, i.e., in food or by immersion in buffer containing the RNA (Gaudilliere et al., 2002; O'Neil et al., 2001; WO99/32619). In another embodiment, dsRNA derived from a gene of the present invention is generated *in vivo* by simultaneously expressing both sense and antisense RNA from appropriately positioned promoters operably linked to coding sequences in both sense and antisense orientations.

c) Peptides and Modified Peptides

[00206] In some embodiments of the present invention, the active agent is a peptide. Suitable peptides include peptides of from about 5 amino acids to about 50, from about 6 to about 30, or from about 10 to about 20 amino acids in length. In some embodiments, a peptide has a sequence of from about 7 amino acids to about 45, from about 9 to about 35, or from about 12 to about 25 amino acids of corresponding naturally-occurring protein. In some embodiments, a peptide exhibits one or more of the following activities: inhibits binding of a subject polypeptide to an interacting protein or other molecule; inhibits subject polypeptide binding to a second polypeptide molecule; inhibits a signal transduction activity of a subject polypeptide; inhibits an enzymatic activity of a subject polypeptide; or inhibits a DNA binding activity of a subject polypeptide.

[00207] Peptides can include naturally-occurring and non-naturally occurring amino acids. Peptides can comprise D-amino acids, a combination of D- and L-amino acids, and various "designer" amino acids (e.g., β -methyl amino acids, C α -methyl amino acids, and N α -methyl amino acids, etc.) to convey special properties. Additionally, peptides can be cyclic. Peptides can include non-classical amino acids in order to introduce particular conformational motifs. Any known non-classical amino acid can be used. Non-classical

amino acids include, but are not limited to, 1,2,3,4-tetrahydroisoquinoline-3-carboxylate; (2S,3S)-methylphenylalanine, (2S,3R)-methyl-phenylalanine, (2R,3S)-methyl-phenylalanine and (2R,3R)-methyl-phenylalanine; 2-aminotetrahydronaphthalene-2-carboxylic acid; hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate; β -carboline (D and L); HIC (histidine isoquinoline carboxylic acid); and HIC (histidine cyclic urea). Amino acid analogs and peptidomimetics can be incorporated into a peptide to induce or favor specific secondary structures, including, but not limited to, LL-Acp (LL-3-amino-2-propenidone-6-carboxylic acid), a β -turn inducing dipeptide analog; β -sheet inducing analogs; β -turn inducing analogs; α -helix inducing analogs; γ -turn inducing analogs; Gly-Ala turn analogs; amide bond isostere; or tetrazol, and the like.

[00208] In addition to the foregoing N-terminal and C-terminal modifications, a peptide or peptidomimetic can be modified with or covalently coupled to one or more of a variety of hydrophilic polymers to increase solubility and circulation half-life of the peptide. Suitable nonproteinaceous hydrophilic polymers for coupling to a peptide include, but are not limited to, polyalkylethers as exemplified by polyethylene glycol and polypropylene glycol, polylactic acid, polyglycolic acid, polyoxyalkenes, polyvinylalcohol, polyvinylpyrrolidone, cellulose and cellulose derivatives, dextran, and dextran derivatives. Generally, such hydrophilic polymers have an average molecular weight ranging from about 500 to about 100,000 daltons, from about 2,000 to about 40,000 daltons, or from about 5,000 to about 20,000 daltons. The peptide can be derivatized with or coupled to such polymers using any of the methods set forth in Zallipsky, (1995); Monfardini et al., (1995); U.S. Pat. Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; 4,179,337, or WO 95/34326.

Antibodies

[00209] The invention provides antibodies that specifically recognize a particular polypeptide. Antibodies are obtained by immunizing a host animal with peptides, polynucleotides encoding polypeptides, or cells, each comprising all or a portion of the target protein ("immunogen"). Suitable host animals include rodents (e.g., mouse, rat, guinea pig, hamster), cattle (e.g., sheep, pig, cow, horse, goat), cat, dog, chicken, primate, monkey, and rabbit. The origin of the protein immunogen can be any species, including mouse, human, rat, monkey, avian, insect, reptile, or crustacean. The host animal will generally be a different species than the immunogen, e.g., a human protein used to

immunize mice. Methods of antibody production are well known in the art (Howard and Bethell, 2000; Harlow et al., 1998; Harlow and Lane, 1988).

[00210] The immunogen can comprise the complete protein, or fragments and derivatives thereof, or proteins expressed on cell surfaces. Immunogens comprise all or a part of one of the subject proteins, where these amino acids contain post-translational modifications, such as glycosylation, found on the native target protein. Immunogens comprising protein extracellular domains are produced in a variety of ways known in the art, e.g., expression of cloned genes using conventional recombinant methods, or isolation from tumor cell culture supernatants, etc. The immunogen can also be expressed *in vivo* from a polynucleotide encoding the immunogenic peptide introduced into the host animal.

[00211] Polyclonal antibodies are prepared by conventional techniques. These include immunizing the host animal *in vivo* with the target protein (or immunogen) in substantially pure form, for example, comprising less than about 1% contaminant. The immunogen can comprise the complete target protein, fragments, or derivatives thereof. To increase the immune response of the host animal, the target protein can be combined with an adjuvant; suitable adjuvants include alum, dextran, sulfate, large polymeric anions, and oil & water emulsions, e.g., Freund's adjuvant (complete or incomplete). The target protein can also be conjugated to synthetic carrier proteins or synthetic antigens. The target protein is administered to the host, usually intradermally, with an initial dosage followed by one or more, usually at least two, additional booster dosages. Following immunization, blood from the host will be collected, followed by separation of the serum from blood cells. The immunoglobulin present in the resultant antiserum can be further fractionated using known methods, such as ammonium salt fractionation, or DEAE chromatography and the like.

[00212] The method of producing polyclonal antibodies can be varied in some embodiments of the present invention. For example, instead of using a single substantially isolated polypeptide as an immunogen, one may inject a number of different immunogens into one animal for simultaneous production of a variety of antibodies. In addition to protein immunogens, the immunogens can be nucleic acids (e.g., in the form of plasmids or vectors) that encode the proteins, with facilitating agents, such as liposomes, microspheres, etc, or without such agents, such as "naked" DNA.

[00213] Antibodies can also be prepared using a library approach. Briefly, mRNA is extracted from the spleens of immunized animals to isolate antibody-encoding sequences. The extracted mRNA may be used to make cDNA libraries. Such a cDNA library may be normalized and subtracted in a manner conventional in the art, for example, to subtract out cDNA hybridizing to mRNA of non-immunized animals. The remaining cDNA may be used to create proteins and for selection of antibody molecules or fragments that specifically bind to the immunogen. The cDNA clones of interest, or fragments thereof, can be introduced into an *in vitro* expression system to produce the desired antibodies, as described herein.

[00214] In a further embodiment, polyclonal antibodies can be prepared using phage display libraries, conventional in the art. In this method, a collection of bacteriophages displaying antibody properties on their surfaces are made to contact subject polypeptides, or fragments thereof. Bacteriophages displaying antibody properties that specifically recognize the subject polypeptides are selected, amplified, for example, in *E. coli*, and harvested. Such a method typically produces single chain antibodies

[00215] Monoclonal antibodies are also produced by conventional techniques, such as fusing an antibody-producing plasma cell with an immortal cell to produce hybridomas. Suitable animals will be used, e.g., to raise antibodies against a mouse polypeptide of the invention, the host animal will generally be a hamster, guinea pig, goat, chicken, or rabbit, and the like. Generally, the spleen and/or lymph nodes of an immunized host animal provide the source of plasma cells, which are immortalized by fusion with myeloma cells to produce hybridoma cells. Culture supernatants from individual hybridomas are screened using standard techniques to identify clones producing antibodies with the desired specificity. The antibody can be purified from the hybridoma cell supernatants or from ascites fluid present in the host by conventional techniques, e.g., affinity chromatography using antigen, e.g., the subject protein, bound to an insoluble support, i.e., protein A sepharose, etc.

[00216] The antibody can be produced as a single chain, instead of the normal multimeric structure of the immunoglobulin molecule. Single chain antibodies have been previously described (i.e., Jost et al., 1994). DNA sequences encoding parts of the immunoglobulin, for example, the variable region of the heavy chain and the variable region of the light chain

are ligated to a spacer, such as one encoding at least about four small neutral amino acids, i.e., glycine or serine. The protein encoded by this fusion allows the assembly of a functional variable region that retains the specificity and affinity of the original antibody.

[00217] The invention also provides intrabodies that are intracellularly expressed single-chain antibody molecules designed to specifically bind and inactivate target molecules inside cells. Intrabodies have been used in cell assays and in whole organisms (Chen et al., 1994; Hassanzadeh et al., 1998). Inducible expression vectors can be constructed with intrabodies that react specifically with a protein of the invention. These vectors can be introduced into host cells and model organisms.

[00218] The invention also provides “artificial” antibodies, e.g., antibodies and antibody fragments produced and selected *in vitro*. In some embodiments, these antibodies are displayed on the surface of a bacteriophage or other viral particle, as described above. In other embodiments, artificial antibodies are present as fusion proteins with a viral or bacteriophage structural protein, including, but not limited to, M13 gene III protein. Methods of producing such artificial antibodies are well known in the art (U.S. Patent Nos. 5,516,637; 5,223,409; 5,658,727; 5,667,988; 5,498,538; 5,403,484; 5,571,698; and 5,625,033). The artificial antibodies, selected for example, on the basis of phage binding to selected antigens, can be fused to a Fc fragment of an immunoglobulin for use as a therapeutic, as described, for example, in US 5,116,964 or WO 99/61630. Antibodies of the invention can be used to modulate biological activity of cells, either directly or indirectly. A subject antibody can modulate the activity of a target cell, with which it has primary interaction, or it can modulate the activity of other cells by exerting secondary effects, i.e., when the primary targets interact or communicate with other cells. The antibodies of the invention can be administered to mammals, and the present invention includes such administration, particularly for therapeutic and/or diagnostic purposes in humans.

[00219] Antibodies may be administered by injection systemically, such as by intravenous injection; or by injection or application to the relevant site, such as by direct injection into a tumor, or direct application to the site when the site is exposed in surgery; or by topical application, such as if the disorder is on the skin, for example.

[00220] For *in vivo* use, particularly for injection into humans, in some embodiments it is desirable to decrease the antigenicity of the antibody. An immune response of a recipient

against the antibody may potentially decrease the period of time that the therapy is effective. Methods of humanizing antibodies are known in the art. The humanized antibody can be the product of an animal having transgenic human immunoglobulin genes, e.g., constant region genes (e.g., Grosveld and Kolia, 1992; Murphy and Carter, 1993; Pinkert, 1994; and International Patent Applications WO 90/10077 and WO 90/04036). Alternatively, the antibody of interest can be engineered by recombinant DNA techniques to substitute the CH1, CH2, CH3, hinge domains, and/or the framework domain with the corresponding human sequence (see, e.g., WO 92/02190). Both polyclonal and monoclonal antibodies made in non-human animals may be "humanized" before administration to human subjects.

[00221] Chimeric immunoglobulin genes constructed with immunoglobulin cDNA are known in the art (Liu et al. 1987a; Liu et al. 1987b). Messenger RNA is isolated from a hybridoma or other cell producing the antibody and used to produce cDNA. The cDNA of interest can be amplified by the polymerase chain reaction using specific primers (U.S. Patent nos. 4,683,195 and 4,683,202). Alternatively, a library is made and screened to isolate the sequence of interest. The DNA sequence encoding the variable region of the antibody is then fused to human constant region sequences. The sequences of human constant regions genes are known in the art (Kabat et al., 1991). Human C region genes are readily available from known clones. The choice of isotype will be guided by the desired effector functions, such as complement fixation, or antibody-dependent cellular cytotoxicity. IgG1, IgG3 and IgG4 isotypes, and either of the kappa or lambda human light chain constant regions can be used. The chimeric, humanized antibody is then expressed by conventional methods.

[00222] Consensus sequences of heavy ("H") and light ("L") J regions can be used to design oligonucleotides for use as primers to introduce useful restriction sites into the J region for subsequent linkage of V region segments to human C region segments. C region cDNA can be modified by site directed mutagenesis to place a restriction site at the analogous position in the human sequence.

[00223] A convenient expression vector for producing antibodies is one that encodes a functionally complete human CH or CL immunoglobulin sequence, with appropriate restriction sites engineered so that any VH or VL sequence can be easily inserted and

expressed, such as plasmids, retroviruses, YACs, or EBV derived episomes, and the like. In such vectors, splicing usually occurs between the splice donor site in the inserted J region and the splice acceptor site preceding the human C region, and also at the splice regions that occur within the human CH exons. Polyadenylation and transcription termination occur at native chromosomal sites downstream of the coding regions. The resulting chimeric antibody can be joined to any strong promoter, including retroviral LTRs, e.g., SV-40 early promoter, (Okayama, et al. 1983), Rous sarcoma virus LTR (Gorman et al. 1982), and Moloney murine leukemia virus LTR (Grosschedl et al. 1985), or native immunoglobulin promoters.

[00224] In yet other embodiments, the antibodies can be fully human antibodies. For example, xenogenic antibodies, which are produced in animals that are transgenic for human antibody genes, can be employed. By xenogenic human antibodies is meant antibodies that are fully human antibodies, with the exception that they are produced in a non-human host that has been genetically engineered to express human antibodies. (e.g., WO 98/50433; WO 98,24893 and WO 99/53049).

[00225] Antibody fragments, such as Fv, F(ab')₂ and Fab can be prepared by cleavage of the intact protein, e.g., by protease or chemical cleavage. These fragments can include heavy and light chain variable regions. Alternatively, a truncated gene can be designed, e.g., a chimeric gene encoding a portion of the F(ab')₂ fragment that includes DNA sequences encoding the CH1 domain and hinge region of the H chain, followed by a translational stop codon. The antibodies of the present invention may be administered alone or in combination with other molecules for use as a therapeutic, for example, by linking the antibody to cytotoxic agent, as discussed above, or to a radioactive molecule. Radioactive antibodies that are specific to a cancer cell, disease cell, or virus-infected cell may be able to deliver a sufficient dose of radioactivity to kill such cancer cell, disease cell, or virus-infected cell. The antibodies of the present invention can also be used in assays for detection of the subject polypeptides. In some embodiments, the assay is a binding assay that detects binding of a polypeptide with an antibody specific for the polypeptide; the subject polypeptide or antibody can be immobilized, while the subject polypeptide and/or antibody can be detectably-labeled. For example, the antibody can be directly labeled or detected with a labeled secondary antibody. That is, suitable, detectable labels for

antibodies include direct labels, which label the antibody to the protein of interest, and indirect labels, which label an antibody that recognizes the antibody to the protein of interest.

[00226] These labels include radioisotopes, including, but not limited to ^{64}Cu , ^{67}Cu , ^{90}Y , ^{124}I , ^{125}I , ^{131}I , ^{137}Cs , ^{186}Re , ^{211}At , ^{212}Bi , ^{213}Bi , ^{223}Ra , ^{241}Am , and ^{244}Cm ; enzymes having detectable products (e.g., luciferase, β -galactosidase, and the like); fluorescers and fluorescent labels, e.g., as provided herein; fluorescence emitting metals, e.g., ^{152}Eu , or others of the lanthanide series, attached to the antibody through metal chelating groups such as EDTA; chemiluminescent compounds, e.g., luminol, isoluminol, or acridinium salts; and bioluminescent compounds, e.g., luciferin, or aequorin (green fluorescent protein), specific binding molecules, e.g., magnetic particles, microspheres, nanospheres, and the like.

[00227] Alternatively, specific-binding pairs may be used, involving, e.g., a second stage antibody or reagent that is detectably-labeled and that can amplify the signal. For example, a primary antibody can be conjugated to biotin, and horseradish peroxidase-conjugated streptavidin added as a second stage reagent. Digoxin and antidigoxin provide another such pair. In other embodiments, the secondary antibody can be conjugated to an enzyme such as peroxidase in combination with a substrate that undergoes a color change in the presence of the peroxidase. The absence or presence of antibody binding can be determined by various methods, including flow cytometry of dissociated cells, microscopy, radiography, or scintillation counting. Such reagents and their methods of use are well known in the art.

Examples

[00228] The examples, which are intended to be purely exemplary of the invention and should therefore not be considered to limit the invention in any way, also describe and detail aspects and embodiments of the invention discussed above. The examples are not intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.

[00229] While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications can be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.

[00230] With respect to ranges of values, the invention encompasses each intervening value between the upper and lower limits of the range to at least a tenth of the lower limit's unit, unless the context clearly indicates otherwise. Further, the invention encompasses any other stated intervening values. Moreover, the invention also encompasses ranges excluding either or both of the upper and lower limits of the range, unless specifically excluded from the stated range.

[00231] Unless defined otherwise, the meanings of all technical and scientific terms used herein are those commonly understood by one of ordinary skill in the art to which this invention belongs. One of ordinary skill in the art will also appreciate that any methods and materials similar or equivalent to those described herein can also be used to practice or test the invention. Further, all publications mentioned herein are incorporated by reference.

[00232] It must be noted that, as used herein, the singular forms "a," "or," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a subject polypeptide" includes a plurality of such polypeptides and reference to "the agent" includes reference to one or more agents and equivalents thereof known to those skilled in the art, and so forth.

[00233] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

[00234] It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description, claims and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings.

References

[00235] The specification is most thoroughly understood in light of the following references, all of which are hereby incorporated by reference in their entireties. The disclosures of the patents and other references cited above are also hereby incorporated by reference.

1. Agrawal, S., Crooke, S.T. eds. (1998) Antisense Research and Application (Handbook of Experimental Pharmacology, Vol 131). Springer-Verlag New York, Inc.
2. Ausubel, F., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A., eds. (1999) Short Protocols in Molecular Biology. 4th ed. Wiley & Sons.
3. Ballance, D.J., Buxton, F.P., Turner, G. (1983) Transformation of *Aspergillus nidulans* by the orotidine-5'-phosphate decarboxylase gene of *Neurospora crassa*. *Biochem. Biophys. Res. Commun.* 112:284-289.
4. Barnes, D., Sato, G. (1980) Methods for growth of cultured cells in serum-free medium. *Anal. Biochem.* 102:255-270.
5. Beach, D., Durkacz, B., Nurse, P. (1982) Functionally homologous cell cycle control genes in budding and fission yeast. *Nature* 300:706-709.
6. Boshart, M., Weber, F., Jahn, G., Dorsch-Hasler, K., Fleckenstein, B., Schaffner, W. (1985) A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. *Cell* 41:521-530.
7. Carbonell, L.F., Hodge, M.R., Tomalski, M.D., Miller, L.K. (1988) Synthesis of a gene coding for an insect-specific scorpion neurotoxin and attempts to express it using baculovirus vectors. *Gene* 73:409-418.
8. Chang, A.C., Nunberg, J.H., Kaufman, R.J., Erlich, H.A., Schimke, R.T., Cohen, S.N. (1978) Phenotypic expression in *E. coli* of a DNA sequence coding for mouse dihydrofolate reductase. *Nature* 275:617-624.
9. Chellaiah et al., *J. Biol. Chem.*, 247(49):34785-34794 (1999)
10. Chen, S.Y., Bagley, J., Marasco, W.A. (1994) Intracellular antibodies as a new class of therapeutic molecule for gene therapy. *Hum. Gene Ther.* 5:595-601.
11. Cregg, J.M., Barringer, K.J., Hessler, A.Y., Madden, K.R. (1985) *Pichia pastoris* as a host system for transformations. *Mol. Cell. Biol.* 5:3376-3385.

12. Cumber et al., *J. Immunology* 149B:120-126 (1992).
13. Das, S., Kellermann, E., Hollenberg, C.P. (1984) Transformation of *Kluyveromyces fragilis*. *J. Bacteriol.* 158:1165-1167.
14. Davidow, L.S., Kaczmarek, F.S., DeZeeuw, J.R., Conlon, S.W., Lauth, M.R., Pereira, D.A., Franke, A.E. (1987) The *Yarrowia lipolytica* LEU2 gene. *Curr. Genet.* 11:377-383.
15. de Boer, H.A., Comstock, L.J., Vasser, M. (1993) The tac promoter: a functional hybrid derived from the trp and lac promoters. *Proc. Natl. Acad. Sci.* 80:21-25.
16. De Louvencourt, L., Fukuhara, H., Heslot, H., Wesolowski, M. (1983) Transformation of *Kluyveromyces lactis* by killer plasmid DNA. *J. Bacteriol.* 154:737-742.
17. Dijkema, R., van der Meide, P.H., Pouwels, P.H., Caspers, M., Dubbeld, M., Schellekens, H. (1985) Cloning and expression of the chromosomal immune interferon gene of the rat. *EMBO J.* 4:761-767.
18. Ehrlich et al., *Biochem* 19:4091-4096 (1980).
19. Gaillardin, C., Ribet, A.M. (1987) LEU2 directed expression of beta-galactosidase activity and phleomycin resistance in *Yarrowia lipolytica*. *Curr. Genet.* 11:369-375.
20. Goeddel, D.V., Heyneker, H.L., Hozumi, T., Arentzen, R., Itakura, K., Yansura, D.G., Ross, M.J., Mizzari, G., Crea, R., Seeburg, P.H. (1979) Direct expression in *E. coli* of a DNA sequence coding for human growth hormone. *Nature* 281:544-548.
21. Gorman, C.M., Merlino, G.T., Willingham, M.C., Pastan, I., Howard, B.H. (1982) The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eucaryotic cells by DNA-mediated transfection. *Proc. Natl. Acad. Sci.* 79:6777-6781.
22. Gray et al., *Biochemistry*, 34:10325-10333 (1995).
23. Grosschedl, R., Baltimore, D. (1985) Cell-type specificity of immunoglobulin gene expression is regulated by at least three DNA sequence elements. *Cell* 41:885-897.
24. Grosveld, F., Kollias, G., eds. (1992) Transgenic Animals. 1st ed. Academic Press.
25. Harlow, E., Lane, D., eds. (1988) Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory.
26. Harlow, E., Lane, D., Harlow, E., eds. (1998) Using Antibodies: A Laboratory Manual: Portable Protocol NO. I. Cold Spring Harbor Laboratory.

27. Hartmann, G., Endres, S., eds. (1999) Manual of Antisense Methodology (Perspectives in Antisense Science). 1st ed. Kluwer Law International.
28. Hassanzadeh, G.H.G., De Silva, K.S., Dambly-Chudiere, C., Brys, L., Ghysen, A., Hamers, R., Muyldermans, S., De Baetselier, P. (1998) Isolation and characterization of single-chain Fv genes encoding antibodies specific for Drosophila Poxn protein. *FEBS Lett.* 437:75-80.
29. Hecht et al., *Growth Factors*, 12:223-233 (1995).
30. Howard, G.C., Bethell, D.R. (2000) Basic Methods in Antibody Production and Characterization. CRC Press.
31. Huston et al., *Proc Natl Acad Sci USA* 85:5879-5883 (1980).
32. Inbar et al., *Proc Natl Acad Sci USA* 69:2659-2662 (1972).
33. Ito, H., Fukuda, Y., Murata, K., Kimura, A. (1978) Transformation of intact yeast cells treated with alkali cations. *J. Bacteriol.* 153:163-168.
34. Johnson, D. & Williams, L., *Adv. Cancer Res.*, 60:1 (1993).
35. Jones, P., ed. (1998a) Vectors: Cloning Applications: Essential Techniques, John Wiley & Son, Ltd.
36. Jones, P., ed. (1998b) Vectors: Expression Systems: Essential Techniques, John Wiley & Son, Ltd.
37. Jost, C.R., Kurucz I., Jacobus, C.M., Titus, J.A., George, A.J., Segal, D.M. (1994) Mammalian expression and secretion of functional single-chain Fv molecules. *J. Biol. Chem.* 269:26,267-26,273.
38. Kabat, E.A., Wu T.T. (1991) Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. *J. Immunol.* 147:1709-1719.
39. Kelly, J.M., Hynes, M.J. (1985) Transformation of *Aspergillus niger* by the mdS gene of *Aspergillus nidulans*. *EMBO J.* 4:475-479.
40. Kunze, G. et al., (1985) Transformation of the industrially important yeasts *Candida maltosa* and *Pichia guilliermondii*. *J. Basic Microbiol.* 25:141-144.
41. Kurtz, M.B., Cortelyou, M.W., Kirsch, D.R. (1986) Integrative transformation of *Candida albicans*, using a cloned *Candida ADE2* gene. *Mol. Cell. Biol.* 6:142-149.

42. Lebacqz-Verheyden, A.M., Kasprzyk, P.G., Raum, M.G., Van Wyke Coelingh, K., Lebacqz, J.A., Battey, J.F. (1988) Posttranslational processing of endogenous and of baculovirus-expressed human gastrin-releasing peptide precursor. *Mol. Cell. Biol.* 8:3129-3135.
43. Liu A.Y., Robinson R.R., Hellstrom K.E., Murray E.D. Jr., Chang C.P., Hellstrom I. (1987a) Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. *Proc. Natl. Acad. Sci.* 84:3439-3443.
44. Liu, A.Y., Robinson, R.R., Murray, E.D. Jr., Ledbetter, J.A., Hellstrom, I., Hellstrom, K.E. (1987b) Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. *J. Immunol.* 139:3521-3526.
45. Luckow, V., Summers, M. (1988) Trends in the development of baculovirus expression vectors. *Bio/Technology* 6:47-55.
46. Maeda, S., Kawai, T., Obinata, M., Fujiwara, H., Horiuchi, T., Saeki, Y., Sato, Y., Furusawa, M. (1985) Production of human alpha-interferon in silkworm using a baculovirus vector. *Nature* 315:592-594.
47. Martin, B.M., Tsuji, S., LaMarca, M.E., Maysak, K., Eliason, W., Ginns, E.I. (1988) Glycosylation and processing of high levels of active human glucocerebrosidase in invertebrate cells using a baculovirus expression vector. *DNA* 7:99-106.
48. Matz, M.V., Fradkov, A.F., Labas, Y.A., Savitsky, A.P., Zaraisky, A.G., Markelov, M.L., Lukyanov, S.A. (1999) Fluorescent proteins from nonbioluminescent *Anthozoa* species. *Nat. Biotechnol.* 17:969-973.
49. McKeehan et al., *Prog. Nucleic Acid Res. Mol. Biol.*, 59:135 (1998).
50. Miyajima A. (2002) Functional analysis of yeast homologue gene associated with human DNA helicase causative syndromes. *Kokuritsu Iyakuin Shokuhin Eisei Kenkyusho Hokoku* 120:53-74.
51. Murphy, D., Carter, D.A., eds. (1993) Transgenesis Techniques: Principles and Protocols. Humana Press.
52. Okayama, H., Berg, P. (1983) A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells. *Mol. Cell. Biol.* 3:280-289.
53. Orr-Urtreger et al., *Dev. Biol.*, 158:475 (1993).
54. Pack et al., *Biochem* 31:1579-1584 (1992)

55. Partanen et al., *Mol. Cell Biol.*, 12:1698 (1992).
56. Peters et al., *Dev. Biol.*, 155:423 (1993).
57. Peelle, B., Gururaja, T.L., Payan, D.G., Anderson, D.C. (2001) Characterization and use of green fluorescent proteins from *Renilla mulleri* and *Ptilosarcus guernyi* for the human cell display of functional peptides. *J. Protein Chem.* 20:507-519.
58. Phillips, M.I., ed. (1999a) Antisense Technology, Part A. Methods in Enzymology Vol. 313. Academic Press, Inc.
59. Phillips, M.I., ed. (1999b) Antisense Technology, Part B. Methods in Enzymology Vol. 314. Academic Press, Inc.
60. Pinkert, C.A., ed. (1994) Transgenic Animal Technology: A Laboratory Handbook. Academic Press.
61. Plontnikov et al., *Cell*, 98:641 (1999).
62. Riechmann et al., *Nature* 332:323-327 (1988).
63. Roggenkamp, R., Janowicz, Z., Stanikowski, B., Hollenberg, C.P. (1984) Biosynthesis and regulation of the peroxisomal methanol oxidase from the methylotrophic yeast *Hansenula polymorpha*. *Mol. Gen. Genet.* 194:489-493.
64. Santos-Ocampo et al., *J. Biol. Chem.*, 271:1726-1731 (1996).
65. Siebenlist, U., Simpson, R.B., Gilbert, W. (1980) *E. coli* RNA polymerase interacts homologously with two different promoters. *Cell* 20:269-281.
66. Smith, G.E., Ju, G., Ericson, B.L., Moschera, J., Lahm, H.W., Chizzonite, R., Summers, M.D. (1985) Modification and secretion of human interleukin 2 produced in insect cells by a baculovirus expression vector. *Proc. Natl. Acad. Sci.* 82:8404-8408.
67. Tilburn, J., Scazzocchio, C., Taylor, G.G., Zabicky-Zissman, J.H., Lockington, R.A., Davies, R.W. (1983) Transformation by integration in *Aspergillus nidulans*. *Gene* 26:205-221.
68. van den Berg, J.A., van der Laken, K.J., van Ooyen, A.J., Renniers, T.C., Rietveld, K., Schaap, A., Brake, A.J., Bishop, R.J., Schultz, K., Moyer, D. (1990) *Kluyveromyces* as a host for heterologous gene expression: expression and secretion of prochymosin. *Bio/Technology* 8:135-139.
69. Verhoeyan et al., *Science* 239:1534-1536 (1988).

70. Vlak, J.M., Klinkenberg, F.A., Zaal, K.J., Usmany, M., Klinge -Roode, E.C., Geervliet, J.B., Roosien, J., van Lent, J.W. (1988) Functional studies on the p10 gene of Autographa californica nuclear polyhedrosis virus using a recombinant expressing a p10-beta- galactosidase fusion gene. *J. Gen. Virol.* 69:765-776.
71. Winter et al., *Nature* 349:293-299 (1991).
72. Yelton, M.M., Hamer, J.E., Timberlake, W.E. (1984) Transformation of *Aspergillus nidulans* by using a trpC plasmid. *Proc. Natl. Acad. Sci.* 81:1470-1474.

References

[001] The specification is most thoroughly understood in light of the following references, all of which are hereby incorporated by reference in their entireties. The disclosures of the patents and other references cited above are also hereby incorporated by reference.

73. Ansel, H.C., Allen, L., Popovich, N.G. eds. (1999) Pharmaceutical Dosage Forms and Drug Delivery Systems. 7th ed. Lippencott Williams and Wilkins Publishers.
74. Beigelman, L., Karpeisky, A., Matulic-Adamic, J., Haeberli, P., Sweedler, D., Usman, N. (1995) Synthesis of 2'-modified nucleotides and their incorporation into hammerhead ribozymes. *Nucleic Acids Res.* 23:4434-4442.
75. Chen, S.Y., Bagley, J., Marasco, W.A. (1994) Intracellular antibodies as a new class of therapeutic molecule for gene therapy. *Hum. Gene Ther.* 5:595-601.
76. Chien, C., Bartel, P.L., Sternglanz, R., Fields S. (1991) The two-hybrid system: A method to identify and clone genes for proteins that interact with a protein of interest. *Proc. Natl. Acad. Sci.* 88:9578-9581.
77. Fields, S., Song, O. (1989) A novel genetic system to detect protein-protein interactions. *Nature* 340:245-246.
78. Furth, P.A., Shamay, A., Wall, R.J., Hennighausen, L. (1992) Gene transfer into somatic tissues by jet injection. *Anal. Biochem.* 205:365-368.
79. Gaudilliere, B., Shi, Y., Bonni, A. (2002) RNA interference reveals a requirement for MEF2A in activity-dependent neuronal survival. *J. Biol. Chem.* 277:46,442-46,446.
80. Gennaro, A., ed. (2000) Remington: The Science and Practice of Pharmacy. 20th ed. Lippincott, Williams, & Wilkins.

81. Gorman, C.M., Merlino, G.T., Willingham, M.C., Pastan, I., Howard, B.H. (1982) The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eucaryotic cells by DNA-mediated transfection. *Proc. Natl. Acad. Sci.* 79:6777-6781.
82. Grosschedl, R., Baltimore, D. (1985) Cell-type specificity of immunoglobulin gene expression is regulated by at least three DNA sequence elements. *Cell* 41:885-897.
83. Grosveld, F., Kollias, G., eds. (1992) Transgenic Animals. 1st ed. Academic Press.
84. Harlow, E., Lane, D., eds. (1988) Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory.
85. Harlow, E., Lane, D., Harlow, E., eds. (1998) Using Antibodies: A Laboratory Manual: Portable Protocol NO. I. Cold Spring Harbor Laboratory.
86. Hartmann, G., Endres, S., eds. (1999) Manual of Antisense Methodology (Perspectives in Antisense Science). 1st ed. Kluwer Law International.
87. Hassanzadeh, G.H.G., De Silva, K.S., Dambly-Chudiere, C., Brys, L., Ghysen, A., Hamers, R., Muyldermans, S., De Baetselier, P. (1998) Isolation and characterization of single-chain Fv genes encoding antibodies specific for Drosophila Poxn protein. *FEBS Lett.* 437:75-80.
88. Hoogenboom, H.R., de Bruin, A.P., Hufton, S.E., Hoet, R.M., Arends, J.W., Roovers, R.C. (1998) Antibody phage display technology and its applications. *Immunotechnology* 4:1-20.
89. Howard, G.C., Bethell, D.R. (2000) Basic Methods in Antibody Production and Characterization. CRC Press.
90. Jameson, D.M., Sawyer, W.H. (1995) Fluorescence anisotropy applied to biomolecular interactions. *Methods Enzymol.* 246:283-300.
91. Kabat, E.A., Wu T.T. (1991) Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. *J. Immunol.* 147:1709-1719.
92. Kibbe, A.H., ed. (2000) Handbook of Pharmaceutical Excipients. 3rd ed. Pharmaceutical Press.
93. Kolonin, M.G., Finley, R.L. Jr. (1998) Targeting cyclin-dependent kinases in *Drosophila* with peptide aptamers. *Proc. Natl. Acad. Sci.* 95:14,266-14,271.

94. Liu A.Y., Robinson R.R., Hellstrom K.E., Murray E.D. Jr., Chang C.P., Hellstrom I.
(1987a) Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells.
Proc. Natl. Acad. Sci. 84:3439-3443.
95. Liu, A.Y., Robinson, R.R., Murray, E.D. Jr., Ledbetter, J.A., Hellstrom, I., Hellstorm, K.E.
(1987b) Production of a mouse-human chimeric monoclonal antibody to CD20 with potent
Fc-dependent biologic activity. *J. Immunol.* 139:3521-3526.
96. Milligan, J.F., Matteucci, M.D., Martin, J.C. (1993) Current concepts in antisense drug
design. *J. Med. Chem.* 36:1923-1937.
97. Monfardini, C., Schiavon, O., Caliceti, P., Morpurgo, M., Harris, J.M., Veronese, F.M.
(1995) A branched monomethoxypoly(ethylene glycol) for protein modification.
Bioconjugate Chem. 6:62-69.
98. Murphy, D., Carter, D.A., eds. (1993) Transgenesis Techniques: Principles and Protocols.
Humana Press.
99. Myers, E.W., Miller, W. (1988) Optimal alignments in linear space. *Comput. Appl. Biosci.*
4:11-7.
100. Okayama, H., Berg, P. (1983) A cDNA cloning vector that permits expression of
cDNA inserts in mammalian cells. *Mol. Cell. Biol.* 3:280-289.
101. O'Neil, N.J., Martin, R.L., Tomlinson, M.L., Jones, M.R., Coulson, A., Kuwabara,
P.E. (2001) RNA-mediated interference as a tool for identifying drug targets. *Am. J.*
Pharmacogenomics 1:45-53.
102. Pinkert, C.A., ed. (1994) Transgenic Animal Technology: A Laboratory
Handbook. Academic Press.
103. Remington, J.P. (1985) Remington's Pharmaceutical Sciences. 17th ed. Mack
Publishing Co.
104. Tang, D.C., DeVit, M., Johnston, S.A. (1992) Genetic immunization is a simple
method for eliciting an immune response. *Nature* 356:152-154.
105. Wagner, R.W., Matteucci, M.D., Grant, D., Huang, T., Froehler, B.C. (1996)
Potent and selective inhibition of gene expression by an antisense heptanucleotide. *Nat.*
Biotechnol. 14:840-844.

106. Wagner, R.W., Matteucci, M.D., Lewis, J.G., Gutierrez, A.J., Moulds, C., Froehler, B.C. (1993) Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. *Science* 260:1510-1513.
107. Xu, C.W., Mendelsohn, A.R., Brent, R. (1997) Cells that register logical relationships among proteins. *Proc. Natl. Acad. Sci. (USA)* 94:12,473-12,478.
108. Zallipsky, S. (1995) Functionalized poly(ethylene glycols) for preparation of biologically relevant conjugates. *Bioconjugate Chem.*, 6:150-165.
109. Zhu, J., Kahn, C.R. (1997) Analysis of a peptide hormone-receptor interaction in the yeast two-hybrid system *Proc. Natl. Acad. Sci.* 94:13,063-13,068.

[00236] What is claimed is:

1. A pharmaceutical composition for treatment of a disease, wherein the composition comprises a pharmaceutically acceptable carrier and at least one modulator that binds to or interferes with the activity of LRP4, LRP8, LRP2 (megalin) and active fragments thereof.

ABSTRACT OF THE DISCLOSURE

The present invention provides pharmaceutical compositions for the treatment of a disease. Compositions of the invention contain a pharmaceutically acceptable carrier and at least one modulator that is capable of binding to or interfere with the activity of megalin, hereinafter referred to as "LRP2," LRP4, LRP8 and active fragments thereof. The invention provides modulators, such as antibodies, RNAi molecules, anti-sense molecules and ribozymes. Additionally, the invention includes methods for the treatment of diseases, such as proliferative diseases and degenerative diseases, and methods of administration of the compositions of the invention.

Table 1

SEQ.ID.NO. 28 HG1014457P1 LRP4_EGF1
CNVNNGGCAQKCQMVRGAVQCTCHTGYRLTEDGHTC

SEQ.ID.NO. 29 HG1014458P1 LRP4_EGF2
CAMENGGCShLCLRSPNPSGFSCPTGINLLSDGKTC

SEQ.ID.NO. 30 HG1014459P1 LRP4_EGF3
CGSRNGGCShLCLPRPSGFSCACPTGIQLKGDGKTC

SEQ.ID.NO. 31 HG1014460P1 LRP4_ldl_recept_a
LCNGVNDCGDNSDESPQQNCRP

SEQ.ID.NO. 32 HG1014461P1 LRP4_ldl_recept_b_1
ELVFWSdVTLDRILRANLINGSNVEEVVSTGLESPGGLAVDWV

SEQ.ID.NO. 33 HG1014462P1 LRP4_ldl_recept_b_2
DKLYWTDSGTSRIEVANLDGAHRKVLWQNLKCPRAIALHPM

SEQ.ID.NO. 34 HG1014463P1 LRP4_ldl_recept_b_3
GTIYWTDWGNTPRIEASSMDGSGRRIIADTHLFWPNGLTIDYA

SEQ.ID.NO. 35 HG1014464P1 LRP4_ldl_recept_b_4
RRMYWVDAKHVIERANLDGSHRKAvisQGLPHFPFAITVFE

SEQ.ID.NO. 36 HG1014465P1 LRP4_ldl_recept_b_5
DHVYWTDVSTDTISRAKWdGTGQEVVVDTSLES PAGLAIDWV

SEQ.ID.NO. 37 HG1014466P1 LRP4_ldl_recept_b_6
NKLYWTDAGTDRIEVANTDGS MRTVLIWENLDRPRDIVVEPM

SEQ.ID.NO. 38 HG1014467P1 LRP4_ldl_recept_b_7
GYMYWTDWGASPKIERAGMDASGRQVISSNLTPNGLAIDYG

SEQ.ID.NO. 39 HG1014468P1 LRP4_ldl_recept_b_8
QRLYWADAGMKTIEFAGLDGSKRKVLIGSQLPHFPGLTLY

SEQ.ID.NO. 40 HG1014469P1 LRP4_ldl_recept_b_9
ERIIYWTDWQTKSIQSADRLTGLDRETLQENLENLMDIHVFHR

SEQ.ID.NO. 41 HG1014470P1 LRP4_ldl_recept_b_10
GKVYWSdSTLHRISRANLDGSQHEDIITTGLQTTDGLAVDAI

SEQ.ID.NO. 42 HG1014471P1 LRP4_ldl_recept_b_11
RKVYWTDGTNRIEVGNLDGSMRKVLVWQNLDS PRAIVLYHE

SEQ.ID.NO. 43 HG1014472P1 LRP4_ldl_recept_b_12
GFMYWTDWGENAKLERSGMDGSDRAVLINNNLGWPNGLTVDKA

SEQ.ID.NO. 44 HG1014473P1 LRP4_ldl_recept_b_13
SQLLWADAHTERIEAADLNGANRHTLVSPVQHPYGLTL

SEQ.ID.NO. 45 HG1014474P1 LRP4_ldl_recept_b_14
GKVYYTDVFLDVIRRADLNGSNMETVIGRGLKTTDGLAVDWV

SEQ.ID.NO. 46 HG1014475P1 LRP4_ldl_recept_b_15
RNLYWTDGTGRNTIEASRLDGSCRKVLINNSLDEPRAIAVFPR

Table 1

SEQ.ID.NO. 47 HG1014476P1 LRP4_ldl_recept_b_16
GYLFWTDWGHIAKIERANLDGSEKVLINTDLGWPNGLTLDYD

SEQ.ID.NO. 48 HG1014477P1 LRP4_ldl_recept_b_17
RRIYWVDAHLDRIESADLNGKLRQVLVGHVSHPFALT

SEQ.ID.NO. 49 HG1014478P1 megalin_EGF_1
CSDFNNGGCTHECVQEPFGAKCLCPLGFLLANDSKTC

SEQ.ID.NO. 50 HG1014479P1 megalin_EGF_2
CDILGSCSQHCYNMRGSFRCSCDTGYMLES DGRTC

SEQ.ID.NO. 51 HG1014480P1 megalin_EGF_3
CLENNGGCSHLCFALPGLHTPKCDCAFGTLQSDGKNC

SEQ.ID.NO. 52 HG1014481P1 megalin_EGF_4
CTEMPVFCSQKCENVIGSYICKCAPGYLREPDGKTC

SEQ.ID.NO. 53 HG1014482P1 megalin_EGF_5
CMHGGNCYFDETDLPKCKCPSGYTGKYC

SEQ.ID.NO. 54 HG1014483P1 megalin_ldl_recept_a_1
QECDSAHFRCGSGHCIPADWRCDGTDKDCSDDADEIGCAV

SEQ.ID.NO. 55 HG1014484P1 megalin_ldl_recept_a_2
VTCQQGYFKCQSEGQCIPSSWVCDQDQDCDDGSDERQDCSQ

SEQ.ID.NO. 56 HG1014485P1 megalin_ldl_recept_a_3
STCSSHQITCSNGQCIPSEYRCDHVRDCPDGADENDCQY

SEQ.ID.NO. 57 HG1014486P1 megalin_ldl_recept_a_4
PTCEQLTCDNGACYNTSQKCDWKVDCRDSSDEINCTE

SEQ.ID.NO. 58 HG1014487P1 megalin_ldl_recept_a_5
CLHNEFSCGNGECIPRAYVCDHDNDCQDGSDEHACNY

SEQ.ID.NO. 59 HG1014488P1 megalin_ldl_recept_a_6
PTCGGYQFTCPSGRCIYQNWVCDGEDDCKDNGDEDCES

SEQ.ID.NO. 60 HG1014489P1 megalin_ldl_recept_a_7
HKCSPREWSCPESGRCISIKVCDGILDCPGREDENNTSTGKYCSM

SEQ.ID.NO. 61 HG1014490P1 megalin_ldl_recept_a_8
EQCGLFSFPCKNGRCVPNYYLCDGVDDCHDNSDEQLCGT

SEQ.ID.NO. 62 HG1014491P1 megalin_ldl_recept_a_9
NTCSSSAFTCGHGECIPAHWRCDKRND CVDGSD EHCNPT

SEQ.ID.NO. 63 HG1014492P1 megalin_ldl_recept_a_10
ASCLDTQYTCDNHQCI SKNWVCDTDNDCGDGSD EKNCNS

SEQ.ID.NO. 64 HG1014493P1 megalin_ldl_recept_a_11
ETCQPSQFNCPNHR CIDLSFVCDGDKDCVDGSD EVGCV

SEQ.ID.NO. 65 HG1014494P1 megalin_ldl_recept_a_12
LNCTASQFKCASGDKCIGVTNRCDGVFDCSDNSDEAGCPT

Table 1

SEQ.ID.NO. 66 HG1014495P1 megalin_ldl_recept_a_13
GMCHSDEFQCQEDGICIPNFWECDGHPDCLYGSDEHNACVP

SEQ.ID.NO. 67 HG1014496P1 megalin_ldl_recept_a_14
KTCPSYFHC DN GN CIHRAWLC DR DNDCG DMSDEKDCPT

SEQ.ID.NO. 68 HG1014497P1 megalin_ldl_recept_a_15
FRCPSWQWQCLGHNICVNLSVVCDGIFDCPNGTDESPLCNG

SEQ.ID.NO. 69 HG1014498P1 megalin_ldl_recept_a_16
ERCGASSFTCSNGRCISEEWKCDNDNDCGDSDEMESVCAL

SEQ.ID.NO. 70 HG1014499P1 megalin_ldl_recept_a_17
HTCSPTAFTCANGRCVQYSYRCDYND CGDGSDEAGCLF

SEQ.ID.NO. 71 HG1014500P1 megalin_ldl_recept_a_18
RDCNATTEFMCNNRRICIPREFICNGVDNCHDNNTSDEKNCPD

SEQ.ID.NO. 72 HG1014501P1 megalin_ldl_recept_a_19
RTCQSGYTKCHNSNICIPRVYLC DGDND CGD NSDENPTYCTT

SEQ.ID.NO. 73 HG1014502P1 megalin_ldl_recept_a_20
HTCSSSEFQCASGRICIPQHWCYDQETDCFDASDEPASCGH

SEQ.ID.NO. 74 HG1014503P1 megalin_ldl_recept_a_21
RTCLADEFKCDGGRCIPSEWICDGDND CGDMSDEDKRHQCQN

SEQ.ID.NO. 75 HG1014504P1 megalin_ldl_recept_a_22
QNCSDSEFLCVNDRPPDRRCIPQSWVCDGDVDCTDGYDENQNCTR

SEQ.ID.NO. 76 HG1014505P1 megalin_ldl_recept_a_23
RTCSENEFTCGYGLCIPKIFRCDRHND CGDYSDERGCLY

SEQ.ID.NO. 77 HG1014506P1 megalin_ldl_recept_a_24
QTCQQNQFTCQNGRCISKTFVCEDEDND CGDGSDELMHLCHT

SEQ.ID.NO. 78 HG1014507P1 megalin_ldl_recept_a_25
PTCPPHEFKCDNGRCIEMMKLCNHLDDCLDNSDEKGC GI

SEQ.ID.NO. 79 HG1014508P1 megalin_ldl_recept_a_26
PMCSSTQFLCANNEKCIPIWWKCDGQKDCSDGSDELALCPQ

SEQ.ID.NO. 80 HG1014509P1 megalin_ldl_recept_a_27
RFCRLGQFQCSDGNCTSPQTLCAHQNCPDGSDEDRLLCEN

SEQ.ID.NO. 81 HG1014510P1 megalin_ldl_recept_a_28
HHCD SNEWQCANKRCIPESWQCDTFND CEDNSDEDS SHCAS

SEQ.ID.NO. 82 HG1014511P1 megalin_ldl_recept_a_29
RTCRPGQFRCANGRCIPQAWKCDVDND CGDHSDEPIEECMS

SEQ.ID.NO. 83 HG1014512P1 megalin_ldl_recept_a_30
EFSCKTNYRCIPKWAVCVNGVDDCRDNSDEQGCEE

SEQ.ID.NO. 84 HG1014513P1 megalin_ldl_recept_a_31
RTCHPVGDFRCKNHHCIPLRWQCDGQND CGD NSDEENCAP

Table 1

SEQ.ID.NO. 85 HG1014514P1 megalin_ldl_recept_a_32
RECTESEFRVCVNQQCIPSRWICDHYND CGDNSDERDCEM

SEQ.ID.NO. 86 HG1014515P1 megalin_ldl_recept_a_33
RTCHPEYFQCTSGHCVHSELKCDGSADCLDASDEADCPT

SEQ.ID.NO. 87 HG1014516P1 megalin_ldl_recept_a_34
AYCQATMFECKNHVCIPPYWKCDGDDDCGDSDEELHLCLD

SEQ.ID.NO. 88 HG1014517P1 megalin_ldl_recept_a_35
VPCNSPNRFRCDNNRCIYSHEVCNGVDDCGDGTDETEEHCRK

SEQ.ID.NO. 89 HG1014518P1 megalin_ldl_recept_a_36
KPCTEY EYKCGNGHCIPHDNVCD DADDCGDSDELGCNK

SEQ.ID.NO. 90 HG1014519P1 megalin_ldl_recept_b_1
QRVFWTDTVQNKVFSVDINGLNIQEVLNVSVETPENLAVDWV

SEQ.ID.NO. 91 HG1014520P1 megalin_ldl_recept_b_2
NKIYLVETKVNRI DMVNLDGSYRVTLITENLGHPRGIAVDPT

SEQ.ID.NO. 92 HG1014521P1 megalin_ldl_recept_b_3
GYLFFSDWESLSGEPKLERAFMDGSNRKDLVKTKLGWPAGVTLDMI

SEQ.ID.NO. 93 HG1014522P1 megalin_ldl_recept_b_4
STIFFSDMSKHMIFKQKIDGTGREILAANRVENVESLAFDWI

SEQ.ID.NO. 94 HG1014523P1 megalin_ldl_recept_b_5
KNLYWTD SHYKSISVMRLADKTRRTVVQY LNNPRSVVVHPF

SEQ.ID.NO. 95 HG1014524P1 megalin_ldl_recept_b_6
GYLFFTDWFRPAKIMRAWSDGSHLLPVINTTLGWPNGLAIDWA

SEQ.ID.NO. 96 HG1014525P1 megalin_ldl_recept_b_7
GRIFWSDATQGKTWSAFQNGTDRRVVFDSSIILTETIAIDWV

SEQ.ID.NO. 97 HG1014526P1 megalin_ldl_recept_b_8
RNLYWTDYALETIEVSKIDGSHRTVLISKNL TNPRGLALDPR

SEQ.ID.NO. 98 HG1014527P1 megalin_ldl_recept_b_9
HLLFWSDWGHHPRIERASMDGSMRTVIVQDKIFWPCGLTIDYP

SEQ.ID.NO. 99 HG1014528P1 megalin_ldl_recept_b_10
GKLYWSDQGTDSGVPKIASANMDGTSVKTLFTGNLEHLECVTLDIE

SEQ.ID.NO. 100 HG1014529P1 megalin_ldl_recept_b_11
QKLYWAVTGRGVIERGNVDGTDRMILVHQLSHPWGIAVH

SEQ.ID.NO. 101 HG1014530P1 megalin_ldl_recept_b_12
RYLFWADYQGRPKIERSFLDCTNRTVLVSEGI VTPRGLAVDRS

SEQ.ID.NO. 102 HG1014531P1 megalin_ldl_recept_b_13
GYLYWADWDTHAKIERATLGGNFRVPIVNSSLVMP SGLTLDYE

SEQ.ID.NO. 103 HG1014532P1 megalin_ldl_recept_b_14
DLLYWVDASLQRIERSTLTGVDREVIVNAAVHAFGLTLY

Table 1

SEQ.ID.NO. 104 HG1014533P1 megalin_ldl_recept_b_15
KRLYWIDTQRQVIERMFLNKTNKETIINHRLPAAESLAVDWV

SEQ.ID.NO. 105 HG1014534P1 megalin_ldl_recept_b_16
RKLYWLDARLDGLFVSDLNGGHRRLAQHCVDANNTFCFDNPRGLALHPQ

SEQ.ID.NO. 106 HG1014535P1 megalin_ldl_recept_b_17
GYLYWADWGHRAYIGRVGMDGTNKSVIISTKLEWPNGITIDYT

SEQ.ID.NO. 107 HG1014536P1 megalin_ldl_recept_b_18
DLLYWADAHLGYIEYSDLEGHHRHTVYDGALPHPFAITIFE

SEQ.ID.NO. 108 HG1014537P1 megalin_ldl_recept_b_19
DTIYWTDWNTRTVEKGKNKYDGSNRQTLVNTTHRPFDIHVYHP

SEQ.ID.NO. 109 HG1014538P1 megalin_ldl_recept_b_20
RHIYWSDEVKNKRIEVAKL DGRYRKWLISTDL DQPAAI AVNP K

SEQ.ID.NO. 110 HG1014539P1 megalin_ldl_recept_b_21
GLMFWTDWGKEPKIESAWMNGEDRNILVFEDLGWPTGLSIDYL

SEQ.ID.NO. 111 HG1014540P1 megalin_ldl_recept_b_22
DRIYWSDFKEDVIETIKYDGTDRRVIAKEA

SEQ.ID.NO. 112 HG1014541P1 LRP8_EGF
CLHNNGGCSHICTDLKIGFECTCPAGFQLLDQKTC

SEQ.ID.NO. 113 HG1014542P1 LRP8_ldl_recept_a_1_v2
KDCEKDQFQCRNERCIPSVWRCEDEDDCLDHSDEDDCPK

SEQ.ID.NO. 114 HG1014543P1 LRP8_ldl_recept_a_2
GTCRGDEFQCGDGTCLVLAIKHCNQEQDCPDGSDEAGCLQ

SEQ.ID.NO. 115 HG1014544P1 LRP8_ldl_recept_a_1
KECEKDQFQCRNERCIPSVWRCEDEDDCLDHSDEDDCPK

SEQ.ID.NO. 116 HG1014545P1 LRP8_ldl_recept_a_3
KTCADSDFTCDNGHCIHERWKCDGEEECPDGSDESEATCTK

SEQ.ID.NO. 117 HG1014546P1 LRP8_ldl_recept_a_4
SHKCVPASWRCDGEKDCEGGADEAGCAT

SEQ.ID.NO. 118 HG1014547P1 LRP8_ldl_recept_a_5
CAPHEFQCGNRSCLA AVF VCDGDDDCGDGSDERGCAD

SEQ.ID.NO. 119 HG1014548P1 LRP8_ldl_recept_a_6
PACGPREFRCGGDGGGACIPERWVCDRQFDCEDRSDEAAELCGR

SEQ.ID.NO. 120 HG1014549P1 LRP8_ldl_recept_a_7
AACATVSQFACRSGECVHLGWRC DGDRDCKDKSDEADCPL

SEQ.ID.NO. 121 HG1014550P1 LRP8_ldl_recept_b_1
NRIYWCDLSYRKIYSAYMDKASDPKEQEV LIDEQLHSPEGLAVDWV

SEQ.ID.NO. 122 HG1014551P1 LRP8_ldl_recept_b_1_v2
NRIYWCDLSYRKIYSAYMDKASDPKEREVLIDEQLHSPEGLAVDWV

Table 1

SEQ.ID.NO. 123 HG1014552P1 LRP8_ldl_recept_b_2
KHIYWTDSGNKTISVATVDGGRRRTLFSRNLSEPRAIAMDPL

SEQ.ID.NO. 124 HG1014553P1 LRP8_ldl_recept_b_3
GFMYWSDWGDQAKIEKSGLNGVDRQTLVSDNIEWPNGITLDLL

SEQ.ID.NO. 125 HG1014554P1 LRP8_ldl_recept_b_4
QRLYWVDSKLHQLSSIDFSGGNRKTLISSTDFLSHPFGIAVFE

SEQ.ID.NO. 126 HG1014555P1 LRP8_ldl_recept_b_5
DKVFWTDLENEAIFSANRLNGLEISILAENLNNPHDIVIFHE

Table 2

FP Patent ID	SEQ.ID.NO. (N1)	SEQ.ID.NO. (P1)	SEQ.ID.NO. (N0)	Classification	Source (aa)	Source (nt)
HG1014438	SEQ.ID.NO. 1	SEQ.ID.NO. 10	SEQ.ID.NO. 19	LRP8	NP_059992	NM_017522
HG1014439	SEQ.ID.NO. 2	SEQ.ID.NO. 11	SEQ.ID.NO. 20	LRP8	NP_150643	NM_033300
HG1014440	SEQ.ID.NO. 3	SEQ.ID.NO. 12	SEQ.ID.NO. 21	LRP8	NP_004622	NM_004631
HG1014441	SEQ.ID.NO. 4	SEQ.ID.NO. 13	SEQ.ID.NO. 22	LRP8	NP_004622_mod_by_CLN00147603	NP_004622_mod_by_CLN00147603
HG1014442	SEQ.ID.NO. 5	SEQ.ID.NO. 14	SEQ.ID.NO. 23	LRP8	H020C00-A-0001_A03.ab1_5pcclone	H020C00-A-0001_A03.ab1_5pcclone
HG1014443	SEQ.ID.NO. 6	SEQ.ID.NO. 15	SEQ.ID.NO. 24	LRP8	PLT00006704_G09.ab1_3pcclone	PLT00006704_G09.ab1_3pcclone
HG1014444	SEQ.ID.NO. 7	SEQ.ID.NO. 16	SEQ.ID.NO. 25	megalin	NP_004516	NM_004525
HG1014445	SEQ.ID.NO. 8	SEQ.ID.NO. 17	SEQ.ID.NO. 26	LRP4	22065231	22065230
HG1014446	SEQ.ID.NO. 9	SEQ.ID.NO. 18	SEQ.ID.NO. 27	LRP4	3449306	3449305
HG1014457		SEQ.ID.NO. 28		LRP4	LRP4_EGF1	
HG1014458		SEQ.ID.NO. 29		LRP4	LRP4_EGF2	
HG1014459		SEQ.ID.NO. 30		LRP4	LRP4_EGF3	
HG1014460		SEQ.ID.NO. 31		LRP4	LRP4_idl_recept_a	
HG1014461		SEQ.ID.NO. 32		LRP4	LRP4_idl_recept_b_1	
HG1014462		SEQ.ID.NO. 33		LRP4	LRP4_idl_recept_b_2	
HG1014463		SEQ.ID.NO. 34		LRP4	LRP4_idl_recept_b_3	
HG1014464		SEQ.ID.NO. 35		LRP4	LRP4_idl_recept_b_4	
HG1014465		SEQ.ID.NO. 36		LRP4	LRP4_idl_recept_b_5	
HG1014466		SEQ.ID.NO. 37		LRP4	LRP4_idl_recept_b_6	
HG1014467		SEQ.ID.NO. 38		LRP4	LRP4_idl_recept_b_7	
HG1014468		SEQ.ID.NO. 39		LRP4	LRP4_idl_recept_b_8	
HG1014469		SEQ.ID.NO. 40		LRP4	LRP4_idl_recept_b_9	
HG1014470		SEQ.ID.NO. 41		LRP4	LRP4_idl_recept_b_10	
HG1014471		SEQ.ID.NO. 42		LRP4	LRP4_idl_recept_b_11	
HG1014472		SEQ.ID.NO. 43		LRP4	LRP4_idl_recept_b_12	
HG1014473		SEQ.ID.NO. 44		LRP4	LRP4_idl_recept_b_13	
HG1014474		SEQ.ID.NO. 45		LRP4	LRP4_idl_recept_b_14	
HG1014475		SEQ.ID.NO. 46		LRP4	LRP4_idl_recept_b_15	
HG1014476		SEQ.ID.NO. 47		LRP4	LRP4_idl_recept_b_16	
HG1014477		SEQ.ID.NO. 48		LRP4	LRP4_idl_recept_b_17	
HG1014478		SEQ.ID.NO. 49		megalin	megalin_EGF_1	
HG1014479		SEQ.ID.NO. 50		megalin	megalin_EGF_2	
HG1014480		SEQ.ID.NO. 51		megalin	megalin_EGF_3	
HG1014481		SEQ.ID.NO. 52		megalin	megalin_EGF_4	
HG1014482		SEQ.ID.NO. 53		megalin	megalin_EGF_5	
HG1014483		SEQ.ID.NO. 54		megalin	megalin_idl_recept_a_1	
HG1014484		SEQ.ID.NO. 55		megalin	megalin_idl_recept_a_2	
HG1014485		SEQ.ID.NO. 56		megalin	megalin_idl_recept_a_3	
HG1014486		SEQ.ID.NO. 57		megalin	megalin_idl_recept_a_4	

Table 2

HG1014487	SEQ.ID.NO. 58	megal	megaln_idl_recept_a_5
HG1014488	SEQ.ID.NO. 59	megal	megaln_idl_recept_a_6
HG1014489	SEQ.ID.NO. 60	megal	megaln_idl_recept_a_7
HG1014490	SEQ.ID.NO. 61	megal	megaln_idl_recept_a_8
HG1014491	SEQ.ID.NO. 62	megal	megaln_idl_recept_a_9
HG1014492	SEQ.ID.NO. 63	megal	megaln_idl_recept_a_10
HG1014493	SEQ.ID.NO. 64	megal	megaln_idl_recept_a_11
HG1014494	SEQ.ID.NO. 65	megal	megaln_idl_recept_a_12
HG1014495	SEQ.ID.NO. 66	megal	megaln_idl_recept_a_13
HG1014496	SEQ.ID.NO. 67	megal	megaln_idl_recept_a_14
HG1014497	SEQ.ID.NO. 68	megal	megaln_idl_recept_a_15
HG1014498	SEQ.ID.NO. 69	megal	megaln_idl_recept_a_16
HG1014499	SEQ.ID.NO. 70	megal	megaln_idl_recept_a_17
HG1014500	SEQ.ID.NO. 71	megal	megaln_idl_recept_a_18
HG1014501	SEQ.ID.NO. 72	megal	megaln_idl_recept_a_19
HG1014502	SEQ.ID.NO. 73	megal	megaln_idl_recept_a_20
HG1014503	SEQ.ID.NO. 74	megal	megaln_idl_recept_a_21
HG1014504	SEQ.ID.NO. 75	megal	megaln_idl_recept_a_22
HG1014505	SEQ.ID.NO. 76	megal	megaln_idl_recept_a_23
HG1014506	SEQ.ID.NO. 77	megal	megaln_idl_recept_a_24
HG1014507	SEQ.ID.NO. 78	megal	megaln_idl_recept_a_25
HG1014508	SEQ.ID.NO. 79	megal	megaln_idl_recept_a_26
HG1014509	SEQ.ID.NO. 80	megal	megaln_idl_recept_a_27
HG1014510	SEQ.ID.NO. 81	megal	megaln_idl_recept_a_28
HG1014511	SEQ.ID.NO. 82	megal	megaln_idl_recept_a_29
HG1014512	SEQ.ID.NO. 83	megal	megaln_idl_recept_a_30
HG1014513	SEQ.ID.NO. 84	megal	megaln_idl_recept_a_31
HG1014514	SEQ.ID.NO. 85	megal	megaln_idl_recept_a_32
HG1014515	SEQ.ID.NO. 86	megal	megaln_idl_recept_a_33
HG1014516	SEQ.ID.NO. 87	megal	megaln_idl_recept_a_34
HG1014517	SEQ.ID.NO. 88	megal	megaln_idl_recept_a_35
HG1014518	SEQ.ID.NO. 89	megal	megaln_idl_recept_a_36
HG1014519	SEQ.ID.NO. 90	megal	megaln_idl_recept_b_1
HG1014520	SEQ.ID.NO. 91	megal	megaln_idl_recept_b_2
HG1014521	SEQ.ID.NO. 92	megal	megaln_idl_recept_b_3
HG1014522	SEQ.ID.NO. 93	megal	megaln_idl_recept_b_4
HG1014523	SEQ.ID.NO. 94	megal	megaln_idl_recept_b_5
HG1014524	SEQ.ID.NO. 95	megal	megaln_idl_recept_b_6
HG1014525	SEQ.ID.NO. 96	megal	megaln_idl_recept_b_7
HG1014526	SEQ.ID.NO. 97	megal	megaln_idl_recept_b_8

Table 2

HG1014527	SEQ.ID.NO. 98	megal	megaln_idl_recept_b_9
HG1014528	SEQ.ID.NO. 99	megal	megaln_idl_recept_b_10
HG1014529	SEQ.ID.NO. 100	megal	megaln_idl_recept_b_11
HG1014530	SEQ.ID.NO. 101	megal	megaln_idl_recept_b_12
HG1014531	SEQ.ID.NO. 102	megal	megaln_idl_recept_b_13
HG1014532	SEQ.ID.NO. 103	megal	megaln_idl_recept_b_14
HG1014533	SEQ.ID.NO. 104	megal	megaln_idl_recept_b_15
HG1014534	SEQ.ID.NO. 105	megal	megaln_idl_recept_b_16
HG1014535	SEQ.ID.NO. 106	megal	megaln_idl_recept_b_17
HG1014536	SEQ.ID.NO. 107	megal	megaln_idl_recept_b_18
HG1014537	SEQ.ID.NO. 108	megal	megaln_idl_recept_b_19
HG1014538	SEQ.ID.NO. 109	megal	megaln_idl_recept_b_20
HG1014539	SEQ.ID.NO. 110	megal	megaln_idl_recept_b_21
HG1014540	SEQ.ID.NO. 111	megal	megaln_idl_recept_b_22
HG1014541	SEQ.ID.NO. 112	LRP8	LRP8_EGF
HG1014542	SEQ.ID.NO. 113	LRP8	LRP8_idl_recept_a_1_v2
HG1014543	SEQ.ID.NO. 114	LRP8	LRP8_idl_recept_a_2
HG1014544	SEQ.ID.NO. 115	LRP8	LRP8_idl_recept_a_1
HG1014545	SEQ.ID.NO. 116	LRP8	LRP8_idl_recept_a_3
HG1014546	SEQ.ID.NO. 117	LRP8	LRP8_idl_recept_a_4
HG1014547	SEQ.ID.NO. 118	LRP8	LRP8_idl_recept_a_5
HG1014548	SEQ.ID.NO. 119	LRP8	LRP8_idl_recept_a_6
HG1014549	SEQ.ID.NO. 120	LRP8	LRP8_idl_recept_a_7
HG1014550	SEQ.ID.NO. 121	LRP8	LRP8_idl_recept_b_1
HG1014551	SEQ.ID.NO. 122	LRP8	LRP8_idl_recept_b_1_v2
HG1014552	SEQ.ID.NO. 123	LRP8	LRP8_idl_recept_b_2
HG1014553	SEQ.ID.NO. 124	LRP8	LRP8_idl_recept_b_3
HG1014554	SEQ.ID.NO. 125	LRP8	LRP8_idl_recept_b_4
HG1014555	SEQ.ID.NO. 126	LRP8	LRP8_idl_recept_b_5

Table 3

CLUSTAL W (1.8) multiple sequence alignment

```

megalin_EGF_2      CDILG-SCSQHCY--NMRGSFRCSCDTGYMLES DGRTC
megalin_EGF_4      CTEMPFVCSQKCE--NVIGSYICKCAPGYLREP DGKTC
LRP4_EGF1          CNVNNGGCAQKCQ--MVRGAVQCTCHTGYRLTED GHTC
LRP4_EGF2          CAMENGGCSHLCLRSPNPSGFSCPTGTGINLLSD GKTC
LRP4_EGF3          CGSRNNGGCSHLCL--PRPSGFSCACPTGTIQLKGD GKTC
megalin_EGF_1      CSDFNNGGCTHECV--QEPFGAKCLCPLGFLLANDS KTC
megalin_EGF_3      CLENNGGCSHLCFALPGLHTPKCDCAFG-TLQSDG KNC
LRP8_EGF           CLHNNGGCSHICT--DLKIGFECTCPAGFQLL-DQK TC
megalin_EGF_5      CMH-GGNCYFDET--DLP---KCKCPSGYT----GKY C
*           *           * * *           : *

```

Table 4

CLUSTAL W (1.8) multiple sequence alignment

```

megalin_ldlra_5      ---CL-HNEFCG-N---GE-----CIPRAYVCDHNDNQDG--SDE---HA--CNY---
megalin_ldlra_36     -KPCT-EYEYKCG-N--GH-----CIPHDNVCDADDCGDW--SDE--LG--CNK---
LRP8_ldlra_6         -PACG-PREFRCG-GDGGGA-----CIPERWVCDRQDFCEDR--SDE--AAELCGR---
LRP4_ldlra          -----LCNGVNDCGDN--SDESPQN--CRP---
megalin_ldlra_19     -RTCQ-SGYTKCH-NS-NI-----CIPRVYLCGDNDNCGDN--SDENP-TY--CTT---
megalin_ldlra_31     -RTCHPVGDFRCK-N--HH-----CIPLRWQCDQNDCGDN--SDE--EN--CAP---
megalin_ldlra_32     -RECT-ESEFRCV-N--QQ-----CIPSRWICDHYNDCGDN--SDE--RD--CEM---
megalin_ldlra_29     -RTCR-PGQFRCA-N--GR-----CIPQAWKCDVDNDCGDH--SDE-PIEE--CMS---
megalin_ldlra_2      -VTCQ-QGYFKCQ-SE-GQ-----CIPSSWVCDQDQDCDDG--SDE-RQD--CSQ---
megalin_ldlra_21     -RTCL-ADEFKCD-G--GR-----CIPSEWICDGDNDCGDM--SDEDKRHQ--CQN---
LRP8_ldlra_1_v2     -KDCE-KDQFQCR-N--ER-----CIPSVWRCEDEDDCLDH--SDE--DD--CPK---
LRP8_ldlra_1        -KECE-KDQFQCR-N--ER-----CIPSVWRCEDEDDCLDH--SDE--DD--CPK---
megalin_ldlra_18     -RDCNATTEFMCN-N--RR-----CIPREFICNGVDNCHDNNTSDE--KN--CPD---
megalin_ldlra_30     -----EFCKTN--YR-----CIPKAVAVCVGDDCRDN--SDE--QG--CEE---
megalin_ldlra_25     -PTCPP-HEFKCD-N--GR-----CIEMMKLCNHLDDCLDN--SDE--KG--CGI---
megalin_ldlra_35     -VPCNSPNRFRCD-N--NR-----CIYSHEVGVGDDCGDGTDETE--EH--CRK---
megalin_ldlra_6      -PTCGG-YQFTCP-S--GR-----CIYQNVVCDGEDDCKDN--GDE--DG--CES---
megalin_ldlra_11     -ETCQP-SQFNCP-N--HR-----CIDLSFVCDGDKDCVDG--SDE--VG--CV---
LRP8_ldlra_5        ---CAP-HEFQCG-N--RS-----CLAAVFCVGDGDDCGDG--SDE--RG--CAD---
megalin_ldlra_8      -EQCGL-FSFPCK-N--GR-----CVPNYVLCVGVDDCHDN--SDE--QL--CGT---
megalin_ldlra_34     -AYCQA-TMFECK-N--HV-----CIPPYWKCDGDDDCGDG--SDEE-LHL--CLD---
megalin_ldlra_17     -HTCS-PTAFTCA-N--GR-----CVQYSYRCYVNDVCGDG--SDE--AG--CLF---
megalin_ldlra_23     -RTCS-ENEFTCG-Y--GL-----CIPKIFRCDRHNDVCGDY--SDE--RG--CLY---
megalin_ldlra_3      -STCS-SHQITCS-N--GQ-----CIPSEYRCDHVRDCPDG--ADE--ND--CQY---
megalin_ldlra_9      -NTCS-SSAFTCG-H--GE-----CIPAHWRCDKRNDVCGD--SDE--HN--CPT---
megalin_ldlra_14     -KTCP-SSYFHCN-N--GN-----CIHRAWLCDRNDNCGDM--SDE--KD--CPT---
megalin_ldlra_10     -ASCL-DTQYTCN-N--HQ-----CISKNVVCDTDNDCGDG--SDE--KN--CNS---
megalin_ldlra_24     -QTCQ-QNQFTCQ-N--GR-----CISKTFVCDENDCGDG--SDEL-MHL--CHT---
megalin_ldlra_4      -PTC--EQLTCD-N--GA-----CYNTSQKCDWKVDCRDS--SDE--IN--CTE---
megalin_ldlra_16     -ERCG-ASSFTCS-N--GR-----CISEWKCDNDNDCGDG--SDEM-ESV--CAL---
LRP8_ldlra_3        -KTCA-DSDFTCN-N--GH-----CIHERWKCDGEECPDG--SDES-EAT--CTK---
megalin_ldlra_1     -QECD-SAHFRCG-S--GH-----CIPADWRCDGTDKCSDD--ADE--IG--CAV---
LRP8_ldlra_4        -----S--HK-----CVPASWRCDGCKDCEGG--ADE--AG--CAT---
megalin_ldlra_12     -LNCT-ASQFKCA-S--GDK-----CIGVTNRCDGVFDCSDN--SDE--AG--CPT---
LRP8_ldlra_7        AACAT-VSQFACR-S--GE-----CVHLGWRCGDRDCDKK--SDE--AD--CPL---
megalin_ldlra_33     -RTCH-PEYFQCT-S--GH-----CVHSELKCDGSADCLDA--SDE--AD--CPT---
megalin_ldlra_27     -RFCR-LGQFQCS-D--GN-----CTSPQTLCAHQNCVPG--SDE--DR--LICEN--
LRP8_ldlra_2        -GTCR-GDEFQCG-D--GT-----CVLAIKHCNQEQDCPDG--SDE--AG--CLQ---
megalin_ldlra_7     -HKCS-PREWSCP-E--SG-----RCISYKVCVCDGILDCPGR--EDEN--NT--STGKYC

```

Table 4

megalin_ldlra_15	-FRCP-SWQWQCL-G---HN-----ICVNLSVVCDGIFDCPNG--TDES--PL--CNG----
megalin_ldlra_13	-GMCH-SDEFQCQ-E---DG-----ICIPNFWECDGHPDCLYG--SDEH--NA--CVP----
megalin_ldlra_26	-PMCS-STQFLCA-N---NE-----KCIPIWWKCDGQKDCSDG--SDEL--AL--CPQ----
megalin_ldlra_22	-QNCSDSEFLCV-N---DRPPDRRCIPQSWVCDGDVDCITDG--YDEN--QN--CTR----
megalin_ldlra_20	-HTCS-SSEFQCA-S---GR-----CIPQHWYCDQETDCFDA--SDEP--AS--CGH----
megalin_ldlra_28	-HHCD-SNEWQCA-N---KR-----CIPESWQCDTFNDCEDN--SDED--SSH-CAS----
	*: *: *
megalin_ldlra_5	--
megalin_ldlra_36	--
LRP8_ldlra_6	--
LRP4_ldlra	--
megalin_ldlra_19	--
megalin_ldlra_31	--
megalin_ldlra_32	--
megalin_ldlra_29	--
megalin_ldlra_2	--
megalin_ldlra_21	--
LRP8_ldlra_1_v2	--
LRP8_ldlra_1	--
megalin_ldlra_18	--
megalin_ldlra_30	--
megalin_ldlra_25	--
megalin_ldlra_35	--
megalin_ldlra_6	--
megalin_ldlra_11	--
LRP8_ldlra_5	--
megalin_ldlra_8	--
megalin_ldlra_34	--
megalin_ldlra_17	--
megalin_ldlra_23	--
megalin_ldlra_3	--
megalin_ldlra_9	--
megalin_ldlra_14	--
megalin_ldlra_10	--
megalin_ldlra_24	--
megalin_ldlra_4	--
megalin_ldlra_16	--
LRP8_ldlra_3	--
megalin_ldlra_1	--
LRP8_ldlra_4	--
megalin_ldlra_12	--

Table 4

LRP8_ldlra_7	--
megalin_ldlra_33	--
megalin_ldlra_27	--
LRP8_ldlra_2	--
megalin_ldlra_7	SM
megalin_ldlra_15	--
megalin_ldlra_13	--
megalin_ldlra_26	--
megalin_ldlra_22	--
megalin_ldlra_20	--
megalin_ldlra_28	--

Table 5

CLUSTAL W (1.8) multiple sequence alignment

```

LRP4_ldlrb9      ERIYWDWQ-TK----SIQSADRLTGLD---RETL---QEN-----LENLMDIHVFHR
LRP8_ldlrb_5     DKVFWTDLE-NE---AIFSANRLNGLE---ISIL---AEN-----LNNPHDIVIFHE
megal_in_ldlrb_19 DTIYWDWN-TR---TVEKGNKYDGSN---RQTL---VNT-----THRPFDIHVYHP
megal_in_ldlrb_22 DRIYWSDFK-ED---VIET-IKYDGTD---RRVI---AKE-----A-----
LRP4_ldlrb11     DKLYWTDG-TS---RIEV-ANLDGAH---RKVL---LWQN---LEKPRAIALHPM
LRP4_ldlrb6      RKVYWTDG-TN---RIEV-GNLDGSM---RKVL---VWQN---LDSPRAIVLYHE
LRP4_ldlrb15     NKLYWTDAG-TD---RIEV-ANTDGSN---RTVL---IWEN---LDRPRDIVVEPM
megal_in_ldlrb_5 RNLYWTDG-RN---TIEA-SRLDGSN---RKVL---INNS---LDEPRAIADFPR
LRP8_ldlrb_2     KNLYWTDGSH-YK---SISV-MRLADKT---RRTV---VQY---LNNPRSVVHPF
megal_in_ldlrb_20 KHIYWTDG-NK---TISV-ATVDGGR---RRTL---FSRN---LSEPRAIADVPL
megal_in_ldlrb_2 RHIYWSVK-NK---RIEV-AKLDGRY---RKWL---ISTD---LDQPAIAVNP
megal_in_ldlrb_8 NKIYLVETK-VN---RIDM-VNLDGSY---RVTL---ITEN---LGHPRGIAVDPT
megal_in_ldlrb_16 RNLYWTDYA-LE---TIEV-SKIDGSH---RTVL---ISKN---LTNPRGLALDPR
megal_in_ldlrb_11 RKLYWLDAR-LD---GLFV-SDLNGGH---RRMLAQHCVDANNTFCFDNPRGLALHPQ
megal_in_ldlrb_12 QKLYWAVTG-RG---VIER-GNVDGTD---RMIL---VHQ---LSHPWGIADVH--
LRP4_ldlrb4      RYLFWADYGQRP---KIER-SFLDCTN---RTVL---VSEG---IVTPRGLAVDRS
LRP8_ldlrb_4     RRMVWDAK-HH---VIER-ANLDGSH---RKAV---ISQG---LPHPFAITVFE-
LRP4_ldlrb13     QRLYWDGSK-LH---QLSS-IDFSGN---RRTL---ISST---FLSHPFGLAVFE-
LRP4_ldlrb17     SOLLWADAH-TE---RIEA-ADLNGAN---RRTL---VS-P---VQHPYGLTL---
megal_in_ldlrb_14 RRIYWVDALD---RIES-ADLNGKL---RQVL---VG-H---VSHPFALT-----
megal_in_ldlrb_18 DLIYWVDAS-LQ---RIER-STLTGVD---REVI---VNAA---V-HAFGLTLY--
LRP4_ldlrb8      QRLYWADAG-MK---TIEF-AGLDGSK---RKVL---IGSQ---LPHPFGLTLY--
LRP4_ldlrb3      GTIYWDWGNTP---RIEA-SSMDGSG---RRIL---ADTH---LFWPNGLTIDYA
megal_in_ldlrb_9 HLLFWSWGHHP---RIER-ASMDGSM---RTVI---VQDK---IFWPCGLTIDYP
megal_in_ldlrb_21 GLMFWTDWKEP---KIES-AWMNGED---RNIL---VFED---LGWPTGLSIDYL
LRP4_ldlrb7      GYMYWTDWGASP---KIER-AGMDASG---RQVI---ISSN---LTPNGLAIDYG
LRP4_ldlrb12     GFMYWTDWGENA---KLER-SGLNGSD---RAVL---INNN---LWPNGLTVDKA
LRP8_ldlrb_3     GFMYWSDWGDQA---KIEK-SGLNGVD---RQTL---VSDN---IEWPNGITLDDL
LRP4_ldlrb16     GYLFWTDWGHIA---KIER-ANLDGSE---RKVL---INTD---LGWPNGLTLDYD
megal_in_ldlrb_6 GYLFFTDWFRPA---KIMR-AWSDGSH---LLPV---INTT---LGWPNGLAIDWA
megal_in_ldlrb_3 GYLFFSDWESLGE-PKLER-AFMDGSN---RKOL---VTK---LGWPAGVTLDMI
megal_in_ldlrb_13 GYLWADWDTHA---KIER-ATLGNF---RVPI---VNSS---LVMPGSLTLDYE
megal_in_ldlrb_17 GYLWADWGHRA---YIGR-VGMDGTN---KSVI---ISTK---LEWPNGITIDYT
megal_in_ldlrb_10 GKLYWSDQGTDSGVPKIAS-ANMDGTS---VKTL---FTGN---LEHLECVTLDIE
LRP4_ldlrb10     GKVYWSDST-LH---RISR-ANLDGSQ---HEDI---ITG---LQTTDGLAVDAI
LRP4_ldlrb14     GKVYITDVF-LD---VIRR-ADLNGSN---METV---IGRG---LKTDDGLAVDWV
LRP4_ldlrb1      ELVFWSDVT-LD---RILR-ANLNGSN---VEEV---VSTG---LESPGGLAVDWV
LRP8_ldlrb_1     NRIYWCDSL-YR---KIYS-AYMDKASDPKEQEVL---IDEQ---LHSPGGLAVDWV

```

Table 5

LRP8_ldlrb_1_v2	NRIYWCDS-YR-----KIYS-AYMDKASDPKEREVL-----IDEQ-----LHSPAGLAVDWV
LRP4_ldlrb5	DHVVWTDVS-TD-----TISR-AKWDGTG-----QEVV-----VDTS-----LESPAGLAIDWV
megalin_ldlrb_1	QRVFWTDTV-QN-----KVFS-VDINGLN-----IQEV-----LNVS-----VETPENLAVDWV
megalin_ldlrb_7	GRIFWSDAT-QG-----KTWS-AFQNGTD-----RRVV-----FDSS-----IILTETIAIDWV
megalin_ldlrb_4	STIFFSDMS-KH-----MIFK-QKIDGTG-----REIL-----AANR-----VENVESLAFDWI
megalin_ldlrb_15	KRLYWIDTQ-RQ-----VIER-MFLNKTN-----KETI-----INHR-----LPAAESLAVDWV
	;

Table 6

CLUSTAL W (1.8) multiple sequence alignment

```

3449306_3449305_EGF2    CAMENGGCShLCLRSPNPSGFSCPTGINLLSDGKTC
3449306_3449305_EGF3    CGSRNGGCShLCL--PRPSGFSCACPTGIQLKGDGKTC
3449306_3449305_EGF1    CNVNNGGCAQKCQ--MVRGAVQCTCHTGYRLTEDGHTC
*  .*****.: *          .....*: * ** . *  **: **

```

Table 7

CLUSTAL W (1.8) multiple sequence alignment

```

3449306_3449305_ldlrb1      ELVFWSDV-TLDRILRAN-LNGSNVEEVVSTGLES PGGLAVDWV
3449306_3449305_ldlrb14     GKVYYTDV-FLDVIRRAD-LNGSNMETVIGRGLKTTDGLAVDWV
3449306_3449305_ldlrb10     GKVYWSDS-TLHRISRAN-LDGSQHEDIITTGLQTTDGLAVDAI
3449306_3449305_ldlrb5      DHVYWTDV-STD TISRAK-WDGTGQEVVVDTSLES PAGLAIDWV
3449306_3449305_ldlrb3      GTIYWTDWGNTPRIEASS-MDGSGRRIIADTHLFWPNGLTIDYA
3449306_3449305_ldlrb7      GYMYWTDWGASPKIERAG-MDASGRQVIISSNLTWPNGLAIDYG
3449306_3449305_ldlrb12     GFMYWTDWGENAKLERSG-MDGSDRAVLINNNLWPNGLTVDKA
3449306_3449305_ldlrb16     GYLFWTDWGHIAKIERAN-LDGSERKVLINTDLGWPNGLTLDYD
3449306_3449305_ldlrb2      DKLYWTDG-GTSRIEVAN-LDGAHRKVLLWQNLEKPRAIALHPM
3449306_3449305_ldlrb11     RKVYWTDG-GTNRIEVGN-LDGSMRKVLVWQNLDSPRAIVLYHE
3449306_3449305_ldlrb6      NKLYWTDG-GTDRIEVAN-TDGSMRTVLIWENLDRPRDIVVEPM
3449306_3449305_ldlrb15     RNLYWTDG-GRNTIEASR-LDGSCRKVLINNSLDEPRAIAVFPR
3449306_3449305_ldlrb13     SQLLWADA-HTERIEAAD-LNGANRHTLVS-PVQHPYGLTL---
3449306_3449305_ldlrb17     RRIYWVDA-HLDRIESAD-LNGKLRQVLVG-HVSHPFALT----
3449306_3449305_ldlrb8      QRLYWADA-GMKTIEFAG-LDGSKRKVLIGSQLPHPFGLTLY--
3449306_3449305_ldlrb4      RRMYWVDA-KHHVIERAN-LDGSHRKAVISQGLPHPFPAITVFE-
3449306_3449305_ldlrb9     ERIYWTDW-QTKSIQSADRLTGLDRETLQE-NLENLMDIHVFHR
      : : *      : . .      : :      :

```

Table 8

CLUSTAL W (1.8) multiple sequence alignment

```

megalin_EGF_2      CDILG-SCSQHCYNMRGSFR--CSCDTGYMLES DGRTC
megalin_EGF_4      CTEMPFVCSQKCENVIGSYI--CKCAPGYLREPDGKTC
megalin_EGF_3      CLENNGGC SHLCFALPGLHTPKDCAFGTLQ-SDGKNC
megalin_EGF_1      CSDFNNGGCTHECVQEP--FGAKCLCPLGFL LANDSKTC
megalin_EGF_5      CMH-GGNCYFDETDLP---K--CKCPSGYT----GKYC
                  *      *              * * *      .: *

```

Table 9

CLUSTAL W (1.8) multiple sequence alignment

```

megalin_ldlra_1      -QECD SA-HFR CG-SG---HCIPADWRC DGT KDCSDD--ADE---IG-CAV-----
megalin_ldlra_12     -LNCTAS-QFKCA-SG---DKCIGVTNRCDGVFDCSDN--SDE---AG-CPT-----
megalin_ldlra_33     -RTCHPE-YFQCT-SG---HCVHSELKCDGSADCLDA--SDE---AD-CPT-----
megalin_ldlra_4       -PTC--E-QLTCD-NG---ACYNTSQKCDWKVDCRDS--SDE---IN-CTE-----
megalin_ldlra_27     -RFCRLG-QFQCS-DG---NCTSPQTL CNAHQNC PDG--SDED-RLL-CEN-----
megalin_ldlra_6       -PTCGGY-QFTCP-SG---RCIYQNWVCDGEDDCKDN--GDE---DG-CES-----
megalin_ldlra_11     -ETCQPS-QFNCP-NH---RCIDL SFVCDGDKDCVDG--SDE---VG-CV-----
megalin_ldlra_18     RDCNATT-EFMCN-NR---RCIPREFICNGVDNCHDNNTSDE---KN-CPD-----
megalin_ldlra_30     -----EF SCKTNY---RCIPKWAVCNGVDDCRDN--SDE---QG-CEE-----
megalin_ldlra_35     VPCNSPN-RFRCD-NN---RCIYSHEVCNGVDDCGDGTDETE---EH-CRK-----
megalin_ldlra_25     -PTCPPH-EFKCD-NG---RCIEMMKLCNHLDDCLDN--SDE---KG-CGI-----
megalin_ldlra_8       -EQCGLF-SFPCK-NG---RCVPNYYLCDGVDDCHDN--SDE---QL-CGT-----
megalin_ldlra_2       -VTCQQG-YFKCQ-SE---GQCIPSSWVCDQDQDCDDG--SDE---RQD-CSQ-----
megalin_ldlra_21     -RTCLAD-EFKCD-G---GRCIPSEWICDGDND CGDM--SDEDKRHQ-CQN-----
megalin_ldlra_14     -KTC PSS-YFHCD-NG--N-CI HRAWLC DRDND CGDM--SDE--KD--CPT-----
megalin_ldlra_19     -RTCQSG-YTKCH-NS--NICIPRVYLC DGDND CGDN--SDE--NPTY-CTT-----
megalin_ldlra_31     -RTCHPVGD FRCK-N---HHCIPLRWQCDGQND CGDN--SDE---EN-CAP-----
megalin_ldlra_32     -RECTES-EFRCV-N---QQCIPSRWICDHYND CGDN--SDE---RD-CEM-----
megalin_ldlra_29     -RTC R PG-QFRCA-N---GRCIPQAWKCDVDND CGDH--SDEP-IEE-CMS-----
megalin_ldlra_10     -ASCLDT-QYTCD-N---HQCISKNWVCDTDND CGDG--SDE---KN-CNS-----
megalin_ldlra_24     -QTCQQN-QFTCQ-N---GRCISKTFVCEDEDND CGDG--SDEL-MHL-CHT-----
megalin_ldlra_34     -AYCQAT-MFECK-N---HVCIPPYWKCDGDDDCGDG--SDEE-LHL-CLD-----
megalin_ldlra_16     -ERCGAS-SFTCS-N---GRCISEEWKCDNDND CGDG--SDEM-ESV-CAL-----
megalin_ldlra_17     -HTCSPT-AFTCA-N---GRCVQYSYRCDYND CGDG--SDE---AG-CLF-----
megalin_ldlra_23     -RTCSEN-EFTCG-Y---GLCIPKIFRCDRHND CGDY--SDE---RG-CLY-----
megalin_ldlra_9       -NTCSSS-AFTCG-H---GECIPAHWRCDKRND CVDG--SDE---HN-CPT-----
megalin_ldlra_3       -STCSSH-QITCS-N---GQCIPSEYRCDHVRDC PDG--ADE---ND-CQY-----
megalin_ldlra_5       ---CLHN-EFSCG-N---GECIPRAYVCDHDND CQDG--SDE---HA-CNY-----
megalin_ldlra_36     -KPCTEY-EYKCG-N---GHCIPHDNVCDADDCGDW--SDE---LG-CNK-----
megalin_ldlra_7       -HKCSPR-EWSC PESG---RCISIYKVCDGILDCPGR--EDE---NNT-STGKYCSM
megalin_ldlra_15     -FRCPSW-QWQCLGHN---ICVNLSVVCDGIFDCPNG--TDE---SPL-CNG-----
megalin_ldlra_13     -GMCHSD-EFQCQEDG---ICIPNFWECDGHPDCLYG--SDE---HNA-CVP-----
megalin_ldlra_26     -PMCSST-QFLCANNE---KCIPIWWKCDGQKDCSDG--SDE---LAL-CPQ-----
megalin_ldlra_22     -QNCSDS-EFLCVNDRPPDRRCIPQSWVCDGDV DCTDG--YDE---NQN-CTR-----
megalin_ldlra_20     -HTCSSS-EFQCASGR---CIPQHWCYCDQETDCFDA--SDE---PAS-CGH-----
megalin_ldlra_28     -HHCD SN-EWQCANKR---CIPESWQCDTFND CEDN--SDE---DSSH CAS-----

```

* * *: :* *

Table 10

CLUSTAL W (1.8) multiple sequence alignment

```

megalin_ldlrb_19      DTIYWTDWNTR---T-VEKGNKYDGSNRQTLVNTTH-----RPFDIHVYHP
megalin_ldlrb_22      DRIYWSDFKED---V-IET- IKYDGTDRRVIAKEA-----
megalin_ldlrb_14      DLLYWVDASLQ---R-IER-STLTGVDREVIVNAAV-----HAFGLTLY--
megalin_ldlrb_18      DLLYWADAHLG---Y-IEY-SDLEGHHRHTVYDGALP-----HPFAITIFE-
megalin_ldlrb_11      QKLYWAVTGGRG---V-IER-GNVDGTDRMILVHQLS-----HPWGIAVH--
megalin_ldlrb_2       NKIYLVETKVN---R-IDM-VNLDGSYRVTLITEN-----LGHPRGIAVDPT
megalin_ldlrb_20      RHIYWSDVKNK---R-IEV-AKLDGRYRKWLISTD-----LDQPAAIAVNP
megalin_ldlrb_5       KNLYWTD SHYK---S-ISV-MRLADKTRRTVVQY-----LNNPRSVVVHPF
megalin_ldlrb_16      RKLYWLDARLD---G-LFV-SDLNGGHRRMLAQHCVDANNTFCFDNPRGLALHPQ
megalin_ldlrb_8       RNLYWTDYALE---T-IEV-SKIDGSHRTVLI SKN-----LTNPRGLALDPR
megalin_ldlrb_12      RYLFWADYGQR---PKIER-SFLDCTNRTVLVSEG-----IVTPRGIAVDRS
megalin_ldlrb_3       GYLFFSDWESLS-GE PKLER-AFMDGSGNRKDLVKTK-----LGWPAGVTLDMI
megalin_ldlrb_6       GYLFFTDWFRP---AKIMR-AWSDGSHLLPVINTT-----LGWPNGLAIDWA
megalin_ldlrb_13      GYLYWADWDTH---AKIER-ATLGGNFRVP IVNSS-----LVMP SGLTLDYE
megalin_ldlrb_9       HLLFWSDWGH---PRIER-ASMDGSMRTVIVQDK-----IFWPCGLTIDYP
megalin_ldlrb_21      GLMFWTDWGKE---PKIES-AWMNGEDRNILVFED-----LGWPTGLSIDYL
megalin_ldlrb_17      GYLYWADWGHR---AYIGR-VGMDGTNKS VIISTK-----LEWPNGITIDYT
megalin_ldlrb_10      GKLYWSDQGTDSGVP AKIAS-ANMDGTSVKTLFTGN-----LEHLEC VTLDIE
megalin_ldlrb_1       QRVFWTDTVQN---K-VFS-VDINGLNIQEVLNVS-----VETPENLAVDWV
megalin_ldlrb_7       GRIFWSDATQG---K-TWS-AFQNGTDRRVVFDSS-----IILTETIAIDWV
megalin_ldlrb_15      KRLYWIDTQRQ---V-IER-MFLNKTNKETI INHR-----LPAAESLAVDWV
megalin_ldlrb_4       STIFFSDMSKH---M-IFK-QKIDGTGREILAANR-----VENVESLAFDWI
      ::                                :

```

Table 11

CLUSTAL W (1.8) multiple sequence alignment

```

LRP8_ldlra_2      GTCRG-DEFQCGD---GTCVLAIKHCNQEQDCPDGSDEA--GCLQ
LRP8_ldlra_5      --CAP-HEFQCGN---RSCLAAVFVCDGDDDCGDSDEA--GCAD
LRP8_ldlra_3      KTCAD-SDFTCDN---GHCIPHERWKCDGEECPDGSDESEATCTK
LRP8_ldlra_6      PACGP-REFRCGGDGGGACIPERWVCDRQFDCEDRSDEAAELCGR
LRP8_ldlra_1_v2   KDCEK-DQFQCRN---ERCIPSVWRCDEDDDCLDHSDED--DCPK
LRP8_ldlra_1      KECEK-DQFQCRN---ERCIPSVWRCDEDDDCLDHSDED--DCPK
LRP8_ldlra_7      AACATVSQFACRS---GECVHLGWRCDGDRDCKDKSDEA--DCPL
LRP8_ldlra_4      -----S---HKCVPASWRCDEKDCGGADEA--GCAT
                  .      *:      *: : :* . :**      *

```


Table 12

CLUSTAL W (1.8) multiple sequence alignment

```
LRP8_ldlrb_2      KHIYWTDSGNKT-ISVATVDGG---RRRTLFSRN--LSEPRAIAVDPL
LRP8_ldlrb_3      GFMYWSDWGDQAKIEKSGLNGV---DRQTLVSDN--IEWPNGITLDLL
LRP8_ldlrb_1      NRIYWCDLSYRK-IYSAYMDKASDPKEQEVLIIDEQ--LHSPEGLAVDWV
LRP8_ldlrb_1_v2   NRIYWCDLSYRK-IYSAYMDKASDPKEREVLIDEQ--LHSPEGLAVDWV
LRP8_ldlrb_5      DKVFWTDLENEAIFSANRLNGL-----EISILAEN--LNNPHDIVIFHE
LRP8_ldlrb_4      QRLYWVDSKLHQ-LSSIDFSGG---NRKTLISSTDFLSHPFGLIAVFE-
                  ::* * . : .. . :. : * :.
```

Table 13

Sequence ID	Pfam	Start	Stop
22065231:22065230	EGF	943	978
22065231:22065230	EGF	636	673
22065231:22065230	ldl_recept_b	809	851
22065231:22065230	ldl_recept_b	1113	1155
22065231:22065230	ldl_recept_b	153	194
22065231:22065230	ldl_recept_b	501	543
22065231:22065230	ldl_recept_b	196	238
22065231:22065230	ldl_recept_b	240	280
22065231:22065230	ldl_recept_b	766	807
22065231:22065230	ldl_recept_b	415	456
22065231:22065230	ldl_recept_b	1070	1111
22065231:22065230	ldl_recept_b	458	499
22065231:22065230	ldl_recept_b	723	764
22065231:22065230	ldl_recept_b	110	151
22065231:22065230	ldl_recept_b	545	584
22065231:22065230	ldl_recept_b	1027	1068
22065231:22065230	ldl_recept_b	586	627
22065231:22065230	ldl_recept_b	1157	1193
22065231:22065230	ldl_recept_b	853	890
3449306:3449305	EGF	984	1019
3449306:3449305	EGF	677	714
3449306:3449305	EGF	29	64
3449306:3449305	ldl_recept_a	1	22
3449306:3449305	ldl_recept_b	850	892
3449306:3449305	ldl_recept_b	1154	1196
3449306:3449305	ldl_recept_b	194	235
3449306:3449305	ldl_recept_b	542	584
3449306:3449305	ldl_recept_b	237	279
3449306:3449305	ldl_recept_b	281	321
3449306:3449305	ldl_recept_b	807	848
3449306:3449305	ldl_recept_b	456	497
3449306:3449305	ldl_recept_b	1111	1152
3449306:3449305	ldl_recept_b	499	540
3449306:3449305	ldl_recept_b	764	805
3449306:3449305	ldl_recept_b	151	192
3449306:3449305	ldl_recept_b	586	625
3449306:3449305	ldl_recept_b	1068	1109
3449306:3449305	ldl_recept_b	627	668
3449306:3449305	ldl_recept_b	1198	1234
3449306:3449305	ldl_recept_b	894	931

Table 14

Sequence ID	Pfam	Start	Stop
NP_004516:NM_004525	EGF	3156	3191
NP_004516:NM_004525	EGF	1394	1428
NP_004516:NM_004525	EGF	1353	1388
NP_004516:NM_004525	EGF	2346	2382
NP_004516:NM_004525	EGF	4383	4410
NP_004516:NM_004525	ldl_recept_a	3633	3673
NP_004516:NM_004525	ldl_recept_a	3717	3756
NP_004516:NM_004525	ldl_recept_a	2862	2901
NP_004516:NM_004525	ldl_recept_a	1065	1103
NP_004516:NM_004525	ldl_recept_a	1269	1307
NP_004516:NM_004525	ldl_recept_a	3073	3111
NP_004516:NM_004525	ldl_recept_a	1147	1184
NP_004516:NM_004525	ldl_recept_a	2739	2777
NP_004516:NM_004525	ldl_recept_a	3030	3070
NP_004516:NM_004525	ldl_recept_a	65	105
NP_004516:NM_004525	ldl_recept_a	2991	3029
NP_004516:NM_004525	ldl_recept_a	3796	3834
NP_004516:NM_004525	ldl_recept_a	2904	2945
NP_004516:NM_004525	ldl_recept_a	1024	1062
NP_004516:NM_004525	ldl_recept_a	3840	3880
NP_004516:NM_004525	ldl_recept_a	2698	2738
NP_004516:NM_004525	ldl_recept_a	1107	1145
NP_004516:NM_004525	ldl_recept_a	220	258
NP_004516:NM_004525	ldl_recept_a	3592	3632
NP_004516:NM_004525	ldl_recept_a	26	64
NP_004516:NM_004525	ldl_recept_a	3510	3550
NP_004516:NM_004525	ldl_recept_a	3757	3795
NP_004516:NM_004525	ldl_recept_a	106	144
NP_004516:NM_004525	ldl_recept_a	3881	3922
NP_004516:NM_004525	ldl_recept_a	183	219
NP_004516:NM_004525	ldl_recept_a	2946	2990
NP_004516:NM_004525	ldl_recept_a	2820	2861
NP_004516:NM_004525	ldl_recept_a	3926	3964
NP_004516:NM_004525	ldl_recept_a	1228	1268
NP_004516:NM_004525	ldl_recept_a	1185	1224
NP_004516:NM_004525	ldl_recept_a	3683	3716
NP_004516:NM_004525	ldl_recept_a	2778	2819
NP_004516:NM_004525	ldl_recept_a	264	309
NP_004516:NM_004525	ldl_recept_a	145	181
NP_004516:NM_004525	ldl_recept_a	3551	3591
NP_004516:NM_004525	ldl_recept_a	1310	1350
NP_004516:NM_004525	ldl_recept_b	3333	3375
NP_004516:NM_004525	ldl_recept_b	1521	1562
NP_004516:NM_004525	ldl_recept_b	3282	3331
NP_004516:NM_004525	ldl_recept_b	4197	4239
NP_004516:NM_004525	ldl_recept_b	1883	1929
NP_004516:NM_004525	ldl_recept_b	1566	1608
NP_004516:NM_004525	ldl_recept_b	4154	4195
NP_004516:NM_004525	ldl_recept_b	838	880
NP_004516:NM_004525	ldl_recept_b	479	520
NP_004516:NM_004525	ldl_recept_b	2519	2561

Table 14

NP_004516:NM_004525	Idl_recept_b	3377	3417
NP_004516:NM_004525	Idl_recept_b	436	477
NP_004516:NM_004525	Idl_recept_b	2202	2244
NP_004516:NM_004525	Idl_recept_b	522	567
NP_004516:NM_004525	Idl_recept_b	796	836
NP_004516:NM_004525	Idl_recept_b	2563	2601
NP_004516:NM_004525	Idl_recept_b	1478	1519
NP_004516:NM_004525	Idl_recept_b	3239	3280
NP_004516:NM_004525	Idl_recept_b	3418	3459
NP_004516:NM_004525	Idl_recept_b	1931	1969
NP_004516:NM_004525	Idl_recept_b	753	794
NP_004516:NM_004525	Idl_recept_b	4242	4271

Table 15

Sequence ID	Pfam	Start	Stop
NP_059992:NM_017522	ldl_recept_a	84	124
NP_059992:NM_017522	ldl_recept_a	45	83
NP_059992:NM_017522	ldl_recept_a	168	206
NP_059992:NM_017522	ldl_recept_a	138	165
NP_059992:NM_017522	ldl_recept_b	423	465
NP_059992:NM_017522	ldl_recept_b	380	421
NP_059992:NM_017522	ldl_recept_b	333	378
NP_059992:NM_017522	ldl_recept_b	467	509
NP_059992:NM_017522	ldl_recept_b	510	551
NP_150643:NM_033300	EGF	170	204
NP_150643:NM_033300	ldl_recept_a	84	124
NP_150643:NM_033300	ldl_recept_a	45	83
NP_150643:NM_033300	ldl_recept_a	138	165
NP_150643:NM_033300	ldl_recept_b	382	424
NP_150643:NM_033300	ldl_recept_b	339	380
NP_150643:NM_033300	ldl_recept_b	426	468
NP_150643:NM_033300	ldl_recept_b	292	337
NP_150643:NM_033300	ldl_recept_b	469	510
NP_004622:NM_004631	ldl_recept_a	84	124
NP_004622:NM_004631	ldl_recept_a	257	296
NP_004622:NM_004631	ldl_recept_a	45	83
NP_004622:NM_004631	ldl_recept_a	167	203
NP_004622:NM_004631	ldl_recept_a	297	335
NP_004622:NM_004631	ldl_recept_a	204	247
NP_004622:NM_004631	ldl_recept_a	138	165
NP_004622:NM_004631	ldl_recept_b	552	594
NP_004622:NM_004631	ldl_recept_b	509	550
NP_004622:NM_004631	ldl_recept_b	596	638
NP_004622:NM_004631	ldl_recept_b	462	507
NP_004622:NM_004631	ldl_recept_b	639	680
NP_004622_mod	ldl_recept_a	84	124
NP_004622_mod	ldl_recept_a	257	296
NP_004622_mod	ldl_recept_a	45	83
NP_004622_mod	ldl_recept_a	167	203
NP_004622_mod	ldl_recept_a	297	335
NP_004622_mod	ldl_recept_a	204	247
NP_004622_mod	ldl_recept_a	138	165
NP_004622_mod	ldl_recept_b	552	594
NP_004622_mod	ldl_recept_b	509	550
NP_004622_mod	ldl_recept_b	596	638
NP_004622_mod	ldl_recept_b	462	507
NP_004622_mod	ldl_recept_b	639	680
H020C00-A-0001_A03.ab1_5pclone	ldl_recept_a	84	124
H020C00-A-0001_A03.ab1_5pclone	ldl_recept_a	45	83
PLT00006704_G09.ab1_3pclone	no_pfam		